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Abstract
Teleglaucoma is a screening device that remotely detects glaucoma cases at earlier
stages using electronically-transferred stereoscopic digital imaging. Thus, patient
wait and travel times are reduced, as well as, patient load in ophthalmic clinics. The
purpose is to synthesize literature to evaluate teleglaucoma: its diagnostic accuracy,
the healthcare system benefits, and its cost-effectiveness. A systematic review was
conducted with published and unpublished studies. A meta-analysis was conducted
to provide estimates of diagnostic accuracy, diagnostic odds ratio, and the relative
percentage of glaucoma cases detected. Using Markov Modelling, a costeffectiveness analysis was conducted. Of 11237 studies reviewed, 45 were included.
Teleglaucoma was more specific and less sensitive than in-person examination. The
pooled estimates of sensitivity was 0.832 [95% CI 0.770, 0.881] and specificity was
0.790 [95% CI 0.668, 0.876]. The ICER calculated for teleglaucoma was
$27,460/QALY. In conclusion, teleglaucoma was found to be more cost-effective
than in-person examination in rural areas.

Keywords
Teleglaucoma, tele-ophthalmology, screening, digital photography, diagnostic
accuracy, glaucoma, ophthalmology, systematic review, meta-analysis, costeffectiveness analysis
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Chapter 1 Introduction

2

1

Introduction
The burden of vision loss on the Canadian economy is $15.8 billion per year in

which 55% is allocated to direct health care costs.1 Sixty-five per cent of adults with
partial or full vision loss are unemployed, which translates to $4.06 CAN billion annually
of lost earnings.1 In the United States, vision loss costs over $35 billion for direct costs
and loss of productivity.2 Glaucoma is the major eye disease leading to irreversible
vision loss. The economic burden of glaucoma alone on the American economy is $2.9
billion.2
Glaucoma tends to be detected at later stages of the disease when glaucoma
has advanced into vision impairment due to peripheral visual field loss. Patients have
“tunnel vision,” but may have perfect central vision. As a result, patients may not notice
visual field loss until advance stages of disease. Detection of glaucoma at earlier stages
is important for treatment and to prevent the progression of disease.3
Teleglaucoma is a screening device that can help detect glaucoma patients at
earlier stages by remotely identifying glaucoma via electronic transmission of highresolution stereoscopic fundus photographs. Teleglaucoma is hypothesized as a more
efficient way of managing glaucoma in rural areas, such as Alberta. Currently this
technology is validated for use in diabetic retinopathy, but recent research has
assessed its performance for glaucoma.4 Teleglaucoma has the potential to reduce
patient wait and travel times in rural areas as well as reduce the patient load in
ophthalmic clinics. The first objective of this study is to synthesize the literature on
teleglaucoma through a systematic review and conduct a meta-analysis to generate the
diagnostic accuracy of teleglaucoma. The second objective is to assess the costeffectiveness of teleglaucoma relative to in-person examination (standard of care).

1.1 Structure of thesis document
This thesis is presented in Integrated-article format in compliance with the standards
outlined by Western University School of Graduate and Postdoctoral studies. Chapter 2
describes the background literature on glaucoma and teleglaucoma. The thesis consists
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of two manuscripts. The first manuscript is “The effectiveness of teleglaucoma versus
in-person examination (Systematic Review and Meta-Analysis)” and it comprises
chapter 3. The second manuscript is “The cost-effectiveness of teleglaucoma versus inperson examination” and it comprises chapter 4. The first objective is addressed in
chapter 3 and the second objective is addressed in chapter 4. Chapter 3 has recently
been published in a peer-reviewed journal and publisher permissions have been
granted to include the paper in this thesis (Appendix 1).5 Portions of chapter 4 have
been conditionally accepted for publication and is now under second review with PLoS
ONE journal.6 Chapter 5, the integrated discussion, summarizes the main results of the
thesis and generates conclusions.

1.2

Literature Cited

1. Canadian National Institute for the Blind (CNIB) and the Canadian
Ophthalmology Society (2009) Costs of vision loss in Canada. Access
Economics Pty Limited Available: http://www.cnib.ca/eng/cnib%20document%2
0library/research/covl_full_report.pdf.
2. Rein DB, Zhang P, Wirth KE et al. (2006) The economic burden of major adult
disorders in the United States. Arch Ophthalmol Dec; 124(12): 1754-60.
3. Hatt S, Wormald R, Burr J (2006) Screening for prevention of optic nerve
damage due to chronic open angle glaucoma. Cochrane Database of Systematic
Reviews Issue 4. Art. No.: CD006129. DOI:0.1002/14651858.CD006129.pub2.
4. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice
Pattern Guidelines. San Francisco, CA; 2008:39. Available at:
http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3219f-487b-a524-326ab3cecd9a.
5. Thomas S-M, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, MalvankarMehta MS. (2014) The Effectiveness of Teleglaucoma versus In-Patient
Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis.
PLoS ONE 9(12): e113779. doi: 10.1371/journal.pone.0113779. pmid:25479593
6. Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness
Analysis of Teleglaucoma Screening Device. PLoS ONE (under second review
2015 June 7).
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Chapter 2 Literature Review, Thesis Rationale, and Thesis
Objective

5

2.1 Literature review
2.1.1 Natural history of glaucoma
Glaucoma is an ophthalmic disease characterized by death of the optic nerve
from excess fluid pressure in the eye. Increased pressure occurs when the trabecular
meshwork can no longer drain excess fluid. Glaucoma is not a singular disease, but a
collection of ophthalmic diseases with various clinical presentations that causes
progressive optic neuropathy. They ultimately end in irreversible vision loss. Glaucoma
is primarily categorized as either open or closed-angle glaucoma:
Open-angle glaucoma (OAG) is the most common type of glaucoma; 90% of
glaucoma cases are open-angle.1 It is caused when the drainage canals clog and
intraocular pressure rises. The angle between the cornea and iris becomes wide
and open. Open-angle glaucoma is also called primary or chronic glaucoma. It
slowly develops and symptoms are not noticed until advanced stages. Glaucoma
presents as mild, moderate, and severe stages. The outer nerves of the eye are
damaged first and causes vision loss starting at the edges of the eye. As it
progresses, vision is lost inward producing “tunnel vision”. Because of this, many
glaucoma patients do not notice their vision loss until the advanced stages of
glaucoma. It is estimated that 50% of those with glaucoma are unaware of their
disease status.2 The focus of this thesis is OAG.
Close-angle glaucoma is also caused by blocked drainage canals and results in
increased intraocular pressure. The angle between the iris and cornea becomes
narrow or closed. Unlike open-angle glaucoma, it develops quickly and vision
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loss is very noticeable. Closed-angle glaucoma requires immediate medical
attention.1
2.1.2 Risk Factors
Intraocular pressure
Intraocular pressure (IOP) is one of the main characteristics of glaucoma. Normal
IOP are pressure levels that do not lead to optic nerve head damage and average
between 12-22 mm Hg.3 As it is measurable, it is a quantitative measure used to
determine glaucoma, but it cannot solely be used for diagnosis. IOP is affected by
several factors including genetics, environment, physiology, ethnicity, refractive error,
and diurnal and postural variations.1,4, These factors on their own can be considered
risk factors for glaucoma. Several genetic studies such as the Blue Mountains Eye
study and Beaver Dam Eye Study have identified chromosomal locations responsible
for fluctuations in IOP.1,5,6 Links between myopia and closed-angle glaucoma in adults
are not definite; some studies have reported either positive or no associations. 1 One of
the main factors affecting IOP and contributing to glaucoma is systemic conditions such
as diabetes mellitus, and hypertension. Smoking, drug use, and dietary exposures can
affect IOP. Smoking can lead to vasoconstriction and increased episcleral venous
pressure. Use of anesthesia drugs (eg. ketamine), illicit drugs (eg. LSD), and systemic
medications (eg. corticosteroids, anticholinergic agents, sulfonamides) may elevate
IOP.1,4 Dietary exposures have not been studied thoroughly, but associations have
been seen between caffeine consumption and increased IOP. Also, consumption of
fruits, vegetables, and omega-3 fatty acids may reduce IOP.1
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Age and Ethnicity
IOP tends to increase as people age naturally. Specifically adults older than 50
years are at higher risk of glaucoma.4,7 The growth of crystalline lens increases as
people age. This causes the anterior chamber to become crowded and closes the angle
within the eye. The risk of glaucoma increases after the age of 40 years.4 The Baltimore
Eye Survey found those who are 70 to 79 of age have a 3.5 times higher prevalence
than those in between 40 to 49 years of age.4,8 Edgar et al reported in those aged 50-59
years, the prevalence of open-angle glaucoma in Black populations was 4.6%, in Asian
populations was 1%, and in Caucasian populations was 0.8%.9 There was an increased
prevalence in all races with increased age: for ages 60-69 years, the prevalence was
7.2% in Black populations, 1.6% in Asians, and 1.6% in Caucasian populations, and for
ages 70-79 years the prevalence was 16%, 3%, and 6%, respectively.9 In older age
groups, women tend to have greater IOP than men specifically after the onset of
menopause.9
Ethnicity can affect IOP. Black populations have been found to have higher IOP
and at greater risk for open-angle glaucoma.1,2,9 The Baltimore Eye Survey found that
black populations have three to four times greater prevalence than Caucasians.8,9
Nonetheless, studies have found Asian populations have increased risk of closed-angle
glaucoma.9,10 Further trends based on ethnicity are detailed in the Epidemiology
section.

8

2.1.3 Epidemiology
Glaucoma is the leading cause of permanent blindness in Canada affecting more
than 400,000 Canadians and 67 million people worldwide.2 Glaucoma is accountable for
14% of all blindness cases.1
Over the past decade there has been several population-based prevalence
surveys of glaucoma globally.1,5,6,8 Of individuals aged 30 years or more, the prevalence
of open-angle glaucoma ranges from 0.03% in China to 8.76% in St. Lucia.9 The
prevalence of glaucoma is increases as people get older. Glaucoma is more prevalent
in certain races. In Caucasian populations, the prevalence of open-angle glaucoma in
those older than 40 years, is approximately 2%.9 However, it has been reported that
Caucasians of comparable age groups have the same prevalence.9 In contrast, there
was higher prevalence in similar age groups reported in Black populations in the
Caribbean and North America.9 In North America, the highest prevalence is seen in the
African-American population, at 8%.9 The age-adjusted rates were 4.3 times higher in
African-Americans than Caucasians Americans.9 In addition, the age of onset is earlier
in African-Americans than in Caucasian Americans.9 The prevalence of glaucoma is
higher in Black Caribbeans than in African-Americans and black populations in Africa.
Specifically, Caribbean countries such as St. Lucia and Barbados have reported the
highest prevalence rates within the Caribbean.9,11 Significant glaucoma studies were
completed in these countries such as the Barbados Eye Study. 9,11
In Asian populations, closed angle glaucoma are more common with a
prevalence of 1%, while the prevalence of open-angle glaucoma is only 0.31%.9
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However, variability has been reported. In Japan, the prevalence of open-angle
glaucoma is greater than closed-angle glaucoma (2.53% versus 0.08% respectively).9
The prevalence differs also for open-angle and closed-angle glaucoma. Openangle glaucoma is most common form of glaucoma in European, Africans, and North
Americans.9
The incidence of glaucoma is 0.04% and 4 out of every 10,000 persons at any
given time will develop glaucoma.4 Studies have reported increased incidence with age:
the five year incidence for those aged 55 years was 0.2% and it increased to 1% for
those aged 75 years.9,12,13 Another study reported the annual incidence in those aged
60-69 years was 12 per 10,000, in those aged 70-79 years incidence was 28 per
10,000, and for those aged 80 years and older incidence was 82 per 10,000.4
Specifically for black populations, the 4-year incidence reported was 55 per 10,000.4
2.1.4 Clinical Assessment of Glaucoma
Glaucoma diagnosis requires several diagnostic tests and imaging based on the
following key characteristics of glaucoma: visual field, intraocular pressure, and optic
nerve head. Each of the key characteristics of glaucoma and the required diagnostic
tests are described in details below.
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Visual Field
Changes in visual field can be used to help detect glaucoma. Visual field loss in
an eye that previously did not have visual field loss can indicate glaucoma. Also,
progressive visual field loss in an eye with previous loss is an important factor. Visual
field defects associated with OAG glaucoma are paracentral defects, arcuate defects,
and nasal steps, as well as, depression in sensitivity, blind spot baring, and increased
blind spot. The main detection technique used is visual inspection followed by
comparison to normal visual field charts. Visual field loss is scored using the Glaucoma
Hemifeld Test (GHT) or Humphrey Visual Field Analyzer (HFA).4
Intraocular Pressure (IOP)
IOP is measured using a tonometer. Applanation tonometry uses the Inbert-Fisck
law which states IOP is equal to the weight applied to the cornea divided by the
applanated area.1 There are two main tonometers: indentation and applanation.
Indentation tonometer has a truncated cone shape and it displaces larger intraocular
volume. Empirical data is used to create a conversion table to measure the IOP. The
second type, the applanation tonometers, has a flattened shape deformation and the
relationship to the IOP can be used to measure the IOP. The applanation tonometer
measures the force that is required to flatten the corneal surface area. This is called the
Goldman applanation tonometer. The Goldman applanation tonometer is widely used
for measuring IOP. It is attached to a slit lamp and it is used to display the circular area
of the cornea into semicircles.1
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Another classification of tonometers are contact and non-contact tonometers.
The Goldman applanation tonometer is a contact tonometer. The probe of the
tonometer comes into contact with the cornea and as a result a topical anesthetic is
used. The anesthetic is applied as an eye drop to the surface of the eye. An example is
proxymetacaine.1
Non-contact tonometers do not come into contact with the eye and instead uses
a puff of air to deform the cornea. It determines the time and the force of the air-puff that
is needed to flatten the cornea. It uses an electro-optical system to detect applanation.
The force detected is used to estimate the IOP. Historically, the accuracy of non-contact
tonometers have been incomparable to contact tonometers and thus, it was a
convenient method for screening IOP. With advances in technology, however, current
non-contact tonometers have correlated higher with the contact tonometers.1
Optic Nerve Head
The optic nerve is responsible for sending visual information from the eye to the
brain and it is located at the back of the eye. The optic nerve head, also known as the
optic disc, is the main pathological feature associated with glaucoma. It is the distal
portion of the optic nerve, which extends from the retinal surface to the myelinated
portion of the optic nerve.1 Retinal nerve fibers converge upon the optic nerve head
which continues to the brain. The optic nerve head is susceptible to elevation of IOP.
Progressive atrophy of the optic nerve head and loss of optic nerve fibers characterize
glaucoma. The optic nerve head is normally shaped with a vertical ovoid referred to as a
cup. The relationship between the diameter of the cup and the diameter of the whole
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optic nerve head is used to diagnose glaucoma. This relationship is called the cup-todisc ratio (CDR).4 Glaucoma increases the size of the cup in a vertical oval-type pattern
thereby increasing the CDR. Defects of the optic nerve are called cupping or a cupped
nerve. One issue with using the CDR is that even within healthy eyes the values may
range. One source reported the CDR of a healthy eye as approximately one third.16
Another reported the average horizontal and vertical CDR as 0.5 and 0.42 respectively.4
There are specific variations within race where African-Americans have significantly
larger CDR than Caucasians.4
Stereoscopic photos of the optic nerve are taken to evaluate for glaucoma. In
addition to the CDR, the ophthalmologist uses the neuroretinal rim and the nerve fiber
layer (NFL) of the optic nerve to determine optic nerve damage. Specifically, the
thickness of neuroretinal rim and NFL should be greatest inferiorly and then the
superior, nasal, and temporal rim; this is known as the ISNT rule.4 Deviation from this
rule is a sign of potential glaucoma. Notching of the neuroretinal rim and/or a thin or
sloped temporal rim are also associated with glaucoma. Thinning of the NFL can be
associated with hemorrhaging. Disc hemorrhaging is seen in 40% of all glaucoma
patients.4 This occurs usually before the neural rim notching or nerve fiber layer and
visual field defects. The hemorrhaging is a result of the glaucomatous damage rather
than a cause. Another sign of glaucomatous damage is the asymmetry of the optic
nerve head between the eyes. Healthy eyes will have no more than a 0.2 difference
between the CDR of the right and left eye.4

13

The traditional instrument for physically examining the optic nerve is the direct
ophthalmoscope. However, it can only generate two-dimensional images, which are
difficult to assess surface contours. Slit-lamp bio-microscope with handheld lens is the
preferred instrument to physically examine the optic nerve.1,4 Additionally, optic disc
stereophotography is used to monitor changes of the optic nerve by comparing older to
recent photographs. Optic nerve head hemorrhaging, notching, neuroretinal rim loss,
and vessel barring can all be seen with optic disc stereophotography.
Optic nerve imaging uses technologies called GDx nerve fiber analyzer,
Heidelberg Retinal Tomography (HRT), and Optical Coherence Tomography (OCT).
GDx nerve fiber analyzer is a scanning laser polarimetry and it measures the
peripapillary retinal nerve fiber layer thickness. It sends laser beams to the posterior
retina and it uses the changes in the retardation of the reflected beam for creation of a
high-resolution image of the optic nerve and peripapillary retina. This techniques
measures the retinal nerve fiber layer (RNFL) thickness. A graphical plot of the RNFL
thickness around the optic nerve, called the double hump, is determined along a 3.2
mm diameter 8-pixel wide circle.4,15,16 In healthy eyes, the superior and inferior poles
have the largest RNFL thickness compared to the nasal and temporal poles.4,15,16
Heidelberg Retinal Tomography (HRT) uses scanning laser tomography to
produce 3-dimensional high-resolution image of the optic nerve.17 HRT provides precise
measurements of optic nerve head parameters that can be used to identify nerve fiber
damage and loss. It uses laser beams to shine light and scan different areas of the
retina.18 The computer develops a calculated image that is used to produce
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measurements of morphometric parameters of the disc.1 This information is used to
classify the nerve as normal or glaucomatous and to measure the disease progression.
A reference ring is placed on the image to define the retinal surface. The cup is the
structure located below the reference plane and the rim is the structure above the
reference plane or within the contour lines. To measure the RNFL thickness, HRT uses
the distance between the reference plane and the retinal surface. 4,18 Moorfields
regression analysis uses the ratio of the rim area to the disc area to determine the
appearance of the optic nerve head as “normal,” “borderline,” and “outside normal
limits.”1,4
Optical Coherence Tomography (OCT) is an imaging technique that applies
the concepts of interferometry. It uses a low-coherence infrared diode light source that
splits into two beams and travels perpendicular to each other. The light is then reflected
with the eye and intersects with the reference beam. The point of intersection creates
an interference signal, which is detected by the interferometer. These signals are then
used to create a cross-sectional image of the retina. The RNFL thickness is measured
by the difference in the delay of backscattered light from the RNFL inside the imaged
tissue.1 This test is non-invasive, involves no contact, and is trans-pupillary. With OCT,
a linear scan of the retina is performed in 1 second while the pupils are dilated. 1 The
images created give the average RNFL thickness in micrometres. Another image of the
retinal displays a colour-coded map of the retinal fibre layers (Figure 1).19 Unlike the
healthy retinal fibre layers shown in Figure 1, a glaucomatous OCT will display a
cupping form within the layers. The OCT can provide measurements of the cup area,
disc area, and cup-to-disc ratio. Comparative images of the left and right eye are
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created to compare the RNFL of both eyes and to analyse the symmetry between eyes.
Asymmetry between the eye can be a sign of glaucomatous loss.20
2.1.5 Glaucoma Screening
Screening and diagnostic tools are significant to prevent glaucoma from
progressing to advanced stages and maintaining healthy vision.21 In addition, glaucoma
prevention will minimize future healthcare costs. The total cost of glaucoma treatment is
estimated to be $1480 for mild, $3682 for moderate, and $4975 for severe forms of
glaucoma.22 Screening can improve the efficiency of the health care system by
increasing the number of patients accessing ophthalmic services and reducing the
number of false-positive referrals to ophthalmologists.23

The standard of care for glaucoma screening consist of routine optometrist visits
every 2-3 years and any glaucoma suspect patient will be referred to an ophthalmologist
for additional diagnostic testing.24 Those of older ages are at a greater risk of glaucoma
and thus ophthalmologists recommend routine optometrist visits every 2 to 4 years for
adults between 40 to 64 years and every 1 to 2 years when aged 65 and older. 21
Patients regularly seen by an ophthalmologist for other ocular conditions may also be
referred for glaucoma diagnostic testing if symptoms appear. In-patient examination will
be referred to as “in-person” examination. In-person examination for glaucoma (passive
“in-person screening”) is performed at specialized clinics and includes detailed history,
slit lamp examination, visual field testing, and fundus photography performed by the
optical technician followed by consultation with the ophthalmologist.25,26 This is
considered no-screening or the “do-nothing” approach where glaucoma suspects go to
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in-person care when symptomatic. The “do-nothing” refers to that fact that the
healthcare providers are not actively searching for potential candidates to screen.
Patients go to visit the optometrist or ophthalmologist when they feel necessary. In
contrast, “active screening” refers to teleglaucoma screening where healthcare
providers actively seek people at-risk of glaucoma within the general population and
these people are encouraged to be screened.

2.1.6 Teleglaucoma Screening

Teleglaucoma is a relatively new screening and diagnostic tool for targeting
remote or under-serviced communities. It uses stereoscopic digital imaging to take
ocular images, which are transmitted electronically to an ocular specialist. The ocular
specialist will then assess the images, identify risk factors, and diagnose for glaucoma.
If necessary, the ocular specialist will refer identified glaucoma cases for medical
consultations or to ophthalmologists for follow-up treatment. Unlike other
teleophthalmology tools, teleglaucoma requires more sophisticated diagnostic tests.
The main tests are optic nerve photographs, Optical Coherence Tomography (OCT),
Intraocular Pressure (IOP) measurements, central corneal thickness (CCT)
measurements, and visual field tests.27-29 The combination of examinations and
equipment required can vary based on organizational resources, target goals, and
populations. However, the more diagnostic tools used during screening for glaucoma
the greater the accuracy and effectiveness of the screening process. The equipment
required for teleglaucoma are the ophthalmic examination equipment, cameras, and
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computer imaging software. The full list of the standard equipment and components of
teleglaucoma can be found in Table 1.27-29

Several studies have reported on the effectiveness of teleglaucoma.
Teleglaucoma technology demonstrated moderate agreement in its ability to diagnose
glaucoma (Kappa statistic 0.55% [0.48, 0.62]).30 When disc damage had Vertical Cup to
Disc Ratio (VCDR) greater than 0.7 the Frequency Doubling Technology (FDT) had a
substantial agreement with the ability to diagnose glaucoma (kappa statistic 0.84).30 In
addition, a study conducted in rural India compared the ability of teleglaucoma to detect
glaucoma compared to standard in-clinic examination and found that there was a good
agreement in detecting glaucoma. For glaucoma the kappa scores were 0.61 with
standard screening versus 0.59 for teleglaucoma.31 In comparison to the in-person slit
lamp examination, the positive predictive value was 77.5% for positive teleglaucoma
diagnosis and it had a negative predictive value of 82.2% for negative teleglaucoma
diagnosis.30 This suggests that the probability of a positive test in a glaucoma positive
case is 77.5%. Also, the probability of a negative test in a glaucoma negative case is
82.2%. However, a cohort study conducted by the University of Alberta found 24% of
teleglaucoma photographs were deemed unreadable from media opacities, patient
cooperation, and unsatisfactory photographic techniques.30
The advantages of teleglaucoma include convenience, decreased travel time to
medical clinics, increased access to specialized care for glaucoma, and decreased
patient costs. The benefits are mainly seen in remote or under-serviced communities
such as Aboriginal communities, rural Manitoba, as well as Alberta where there is
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limited ocular specialists. Teleglaucoma wait time reduction was 41% versus 19% with
in-person examinations.32 Arora et al. reported improved access time (time from patient
being referred to the date visit is booked) of 45 days with teleglaucoma versus 88 days
for standard in-person examinations.38 Teleglaucoma had reduced cycle time (time from
registration until patient leaves clinic) of 78 minutes versus in-person exam of 115
minutes.32 The pioneer teleglaucoma study conducted in Finland reported reduced
absence from work by 50% with teleglaucoma versus in-person examination, and in
addition reduced traveling (97%), costs (92%), and time (92%).33
2.1.7 Systematic Review
The purpose of systematic reviews (SR) is to synthesize research literature from
published and unpublished sources about a research topic.34 There are several steps in
the process of conducting a systematic review.34,35 First is to define the question. It is
important to specify the inclusion and exclusion criteria, the population, the intervention,
the outcome, and methodology. The second step is to conduct the literature search.
This involves choosing information sources both published and unpublished sources
and identifying titles and abstracts. Once the articles are generated and organized into
the database the articles are then screened using the inclusion and exclusion criteria.
Level 1 screening is applied to titles and abstracts. Level 2 screening involves obtaining
full text articles for eligible studies and applying the inclusion and exclusion criteria. Two
reviewers conduct the screening. At each stage, the reviewers compare agreements
and disagreements to ensure article eligibility. If disagreements occur, then a third
reviewer intervenes and makes the decision. The fourth step is to create a database
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with important study variables. The data extraction is then conducted and information is
collected on each study’s population, interventions, comparison, and study design. In
addition, other study variables include the results, methodologic quality, and validity
agreement. The last step is to conduct the analysis and generate pooled estimates. It is
important to assess variability amongst studies, which is the level of heterogeneity.
Publication bias, a common bias affecting systematic reviews, is the selective
publication of studies. Publication bias is tested using funnel plots.
Systematic reviews are useful for determining if study results are valid. It
analyzes the methodologic quality of studies and it examines the reproducibility of
studies. It summarizes the results and determines if there is variability in study results. It
also gives the precision of results.35 The significance of systematic reviews is that it
gives the summary of all research literature in one document. This makes it easy for
clinicians, policy makers, and healthcare care administrators to be informed of the
evidence. It provides pooled estimates necessary for decision makers to make
evidence-based decisions. Systematic reviews are useful for determining important
patient outcomes and furthermore, how to apply the results to patient care.
2.1.8 Meta-analysis
Meta-analysis are a continuation of systematic reviews that add precision to the
synthesized results. They are a formal, quantitative study to assess the strength of
existing evidence on the specific research question. The meta-analysis is beneficial to
determine if a treatment effect exists, if the effect size is positive or negative, and the
relative treatment effect in comparison to the comparator.36
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The statistical analysis involves the calculations of effects sizes in forms of risk
ratios, odds ratios, and standardized mean differences depending on the exact study
purpose. Studies are weighted for analysis based on the value of the evidence in each
study and its sample size. More specifically studies are weighted according to the
inverse of their variance.36 Thus, studies with smaller sample sizes will contribute less to
the pooled estimate of effect size. There are two main models used in meta-analysis
when generating the effect sizes: fixed effects and random-effects models.36 In the
fixed-effects model, the source of variation in study results occurs from within each
study. This model is homogenous, which means that the study treatments, populations,
and other study variables are the same amongst studies. In contrast, the random-effects
model assumes there is heterogeneity among study results. Studies are weighted by
the inverse of their variance and the heterogeneity parameter.

Hierarchical logistic regression model is another model that incorporates aspects
of both fixed-effect and random-effect models.37 It is used for mixed models that have a
group structure.38 The theory of hierarchical modelling is that at the micro level the
normal logistic regression is used, but the coefficients may vary for each macro level
observation. At the macro level, the micro level coefficients are functions of the macro
level regression.39 Hierarchical models are useful for multilevel analysis where there is
within study variance, as well as, between study variance.39 This is because hierarchical
models are good for modelling specificity and sensitivity. This model is also useful for
measures with binary responses. In addition, it is useful for meta-analyses as it takes
into consideration the effects of study-specific covariates.
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From the hierarchical regression modeling a Hierarchical Summary Receiver
Operating Curve (HSROC) is generated, which provides the accuracy of the screening
tool. It graphs both sensitivity and specificity to give a pooled estimate from all of the
reported study estimates. The pooled estimate lies within a line or curve called the
“summary line”.40 Summary lineis used when there are no covariates and is calculated
using parameters from the bivariate model. The summary line shows the range of the
pooled estimates of sensitivity and specificity separately, and it represents the
relationship between specificity and sensitivity.40 Therefore, it demonstrates how
changing the summary specificity affects the summary sensitivity.

Both the summary estimate and the summary line are interpreted against the
clinical threshold to determine if the screening tool is accurate or not. Firstly, the
curvature of the line is important; if there is a positive upward slope, this shows there is
a positive relationship between specificity and sensitivity.40 Secondly, the area under the
curve represents the accuracy. The greater the area under the curve the higher the
accuracy. Generally, if the HSROC lies above the threshold line, which lies at a 45
degree angle, then the accuracy is better than random chance.40 Also, if the HSROC
lies above the clinical threshold stipulated by physicians or health experts then that
screening tool is deemed clinically acceptable.40

The HSROC curve also provides the 95% confidence region which is the
confidence interval of the summary estimate. The confidence region is the range of
estimates that are likely to include the true estimate with 95% probability.41 HSROC also
gives the 95% prediction region, which is the region that the future observation will fall
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given the existing data with 95% probability.41 Both measures are useful for researchers
and clinicians to understand the distribution of the data, and the predicted data. It also
gives the statistical significance of the summary estimate. The wider the confidence or
prediction regions, the less statistically significant the summary estimates.

One of the benefits of meta-analysis is it assesses the sources of heterogeneity
among studies.35 Note, one of the purposes of meta-analyses is to determine which
treatment/intervention is more effective. Thus, identifying the sources of heterogeneity
can assist in interpreting the results and generating the conclusions of the metaanalysis. Study results should be interpreted with caution when heterogeneity, the
variation among studies, exists.36 This may call for subgroup analysis to determine the
factors or covariates affecting the study results.

There are two kinds of variability in studies: clinical diversity and methodological
diversity.36 Clinical diversity is the variability in the study’s population, intervention,
and/or measures. Whereas, methodological diversity is the variability in the study
design and its related risks of bias.
Heterogeneity is quantified using the inconsistency index I 2. The I2 is given by a
percentage of total variation across studies and ranges from 0 to 100%. 35,36 If I2 is
greater than 75% then there is substantial heterogeneity amongst studies.35,36

Both systematic reviews and meta-analysis have been used extensively in
ophthalmology to synthesize ophthalmic literature on glaucoma, diabetic retinopathy,
cataracts, and all other eye diseases. They have been applied to determine the

23

effectiveness of many interventions including the effectiveness of screening strategies.
The Cochrane Review has published a systematic review on the effectiveness of
screening for glaucoma and found that screening is effective in glaucoma populations
specifically when targeting at-risk population.21

Several systematic reviews and meta-analysis have been conducted on
teleophthalmology use for diabetic retinopathy, however, no studies have looked at the
literature on teleglaucoma as discussed earlier.
2.1.9 Specificity and Sensitivity
The two main measures of screening effectiveness are specificity and sensitivity.
Both are independent of the population or prevalence. Specificity is the ability of the test
to correctly detect the people who do not have the disease.40 Statistically it is calculated
by the number of negative tests divided by those without the disease.42 The
denominator are those without the disease which include both the true negatives cases
who test negative (true negatives) and the negative cases who test positive (false
positives).
Sensitivity is the ability of the test to correctly detect positive cases in those with
the disease.40 The higher the sensitivity the more effective the test is at detecting
positive cases. Statistically, it is calculated by the number of true positives tests divided
by the number of people with the disease.42 Likewise, the denominator are those with
the disease which include both the true positive cases who test positive (true positive)
and the true positive cases who test negative (false negatives).
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For teleglaucoma, both the sensitivity and specificity are important; it is good
practice to detect both the negative and positive cases correctly for efficient patient care
and patient health outcomes. However, the sensitivity of teleglaucoma is particularly
important because it incorporates the false negatives.42 The false negatives are the
patients who have the disease and are incorrectly detected as a negative test. This
patient group will be told they do not have the disease and continue living as normal.
However, with glaucoma, this is particularly crucial to avoid. Glaucoma is a silent thief of
vision and if left untreated patient can lose substantial visual acuity as well as suffer
from visual defects. Thus, the sensitivity of teleglaucoma is important to prevent
glaucoma cases from leaving the clinic without appropriate medical care.

2.1.0 Cost-Effectiveness Analysis
Economic evaluations are an essential part of healthcare. Specifically, costeffectiveness analysis (CEA) is an economic evaluation used by policy makers and
healthcare administers to make decisions in healthcare.43 Directions in health care, as
well as other areas of the public sectors, are based primarily on funding and the
expected benefits.43,44 Hence, CEA describes the relationship between the costs and
the effects (expected benefits) of interventions. CEA provides the evidence of where
healthcare funds should be applied. Thus, the significance of CEA is that, it determines
resource allocation and which health programs/interventions are funded.
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In terms of ophthalmology, CEA is useful for comparing the costs and effects of
different treatments for glaucoma, diabetic retinopathy, cataracts, etc. This economic
evaluation can help determine which intervention is cost-effective and should be
implemented. In addition, the beauty of CEA is that it can use quality of life measures as
the effect data, such as quality-adjusted life years (QALY) or utility values.43 Thus, an
intervention in glaucoma that increases the visual field by 15% which is equivalent to
improvement of 0.12 QALYs, is equivalent to a cardiac intervention that reduces blood
flow by 0.02%, which is also equivalent to a 0.12 QALY improvement. This allows
comparison of ophthalmic interventions to non-ophthalmic interventions. Thus, CEA
provides healthcare administrators and policy makers’ essential tools to allocate
resources among different health care areas.43 CEAs can generate conclusions on the
benefits to the health care system and improvements in health service quality. More
specifically, glaucoma is a chronic and progressive disease. As discussed earlier, there
is no cure for glaucoma, hence the cumulative cost of living with the disease increases
as patients live longer with the disease and increase substantially as the patients
progress to advanced stages. CEA can be beneficial at assessing the long term costs
and benefits associated with glaucoma.44 It is important to know the long term benefits
after interventions for glaucoma are implemented. Also, CEAs can provide the long term
patient health outcomes and its associated costs, which is essential to health care
planning.
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2.1.11 Conclusion
Overall, teleglaucoma has potential to increase the access to ophthalmic care in
rural and under-serviced areas where there is either limited ophthalmologists or
requirement of a long travel. It is predicted that with teleglaucoma, there will be
increased quality of life in patients with glaucoma. With progressive permanent vision
loss as the main factor affecting a patient’s quality of life, detecting glaucoma patients
through screening can assist to prevent vision impairment.

2.2 Thesis Rationale
Current health reforms are shifting towards “e-health;” the incorporation of
technology within healthcare to bring together distant communities and to improve
access to expert medical advice and diagnosis.45,46 Telemedicine facilitates
communications across geographic borders and across interdisciplinary networks. In
many areas of health care, telemedicine has allowed more informed decision making
and improved quality of care.45-48 It is efficient and convenient and it has benefits to
improving the efficiency of administration.47,48 Telemedicine has demonstrated costeffectiveness in delivery of care for other health diseases.45,46 Specifically, rural and
elderly populations both benefit from remote in-home consultation.47,48
The use of telemedicine in ophthalmology (tele-ophthalmology) is not a new
concept. Several studies have examined the use of tele-ophthalmology for screening of
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diabetic retinopathy and found tele-ophthalmology played an effective role in screening
diabetic retinopathy.49-542-57 However, few studies have examined the use of teleophthalmology for glaucoma screening, in terms of its sensitivity, specificity, and timesavings.
Tele-ophthalmology is an emerging screening technique that can be effective for
glaucoma detection for several reasons. Firstly, glaucoma is an age-related disease
affecting the elderly populations. Teleglaucoma allows remote consultations which
reduces travel time, and thus, the elderly population may benefit from the convenience
of teleglaucoma.45,48,49 It promotes senior wellness and improved quality of life for the
elderly. Secondly, glaucoma causes peripheral vision loss initially as opposed to
diminishing visual acuity. As a result, patients may not notice visual field defects initially.
It has been reported that 50% of cases are not detected until the advanced stages of
the disease.2 Introduction of teleglaucoma can detect cases that may not have been
detected otherwise.28 It is hypothesized that screening of elderly populations and
populations at-risk will detect potential cases and cases at earlier stages of the disease.
In addition, vision loss and visual defects due to glaucoma are permanent.
Teleophthalmology would be beneficial to glaucoma patients as it can capture cases
earlier thereby avoiding vision loss and permanent blindness. In return, preserving
vision through teleglaucoma will improve the quality of life of patients. Therefore, the
thesis rationale is that tele-ophthalmology may have a significant contribution for
glaucoma management and have a significant impact on glaucoma patients.
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Research has been conducted on the effectiveness of teleglaucoma and the
direct benefits to patients and the healthcare system. However, to date, there is no
synthesis of the research data. Synthesized effectiveness data is required to make
informed decisions and to implement this technology for glaucoma screening.
Healthcare decisions are based on research evidence. In addition, there are cost
implications for implementing teleglaucoma. Research on the cost-effectiveness of
teleglaucoma has not been published in research literature. This thesis will contribute to
research literature by synthesizing the data on the effectiveness of teleglaucoma and
analyzing the cost-effectiveness of teleglaucoma.

2.3 Thesis Objectives
There are two objectives of this thesis. The first objective is to determine the
effectiveness of teleglaucoma in-comparison to standard in-person examination for
glaucoma screening. This thesis will synthesize information on diagnostic accuracy,
benefits to health care service quality, and improvements to patient quality of life. The
second objective is to determine the cost-effectiveness of teleglaucoma in rural areas
for at-risk populations.
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2.5 Tables
Table 2.1 Standard teleglaucoma equipment
Components
Human Resources

Information Technology

Screening Equipment

Examinations

Requirements
Staff: graders, Ophthalmic technicians, nurses,
optometrist, physicians, glaucoma
specialists/ophthalmologists
Secure Diagnostic Imaging (SDI) system
Videoconferencing equipment
Computer systems and software
ISDN installation
Retinal camera
Tonometer
Devices to measure central corneal thickness
Frequency Doubling Technology (FDT) or Humphrey
Visual Field test
Optical Coherence Tomography
Slit lamp
Gonioscope
Medical & family history
Visual acuity
IOP
CCT
Pupil equal and reactive to light (PERL) or relative afferent
pupillary defect (RAPD)
Slit lamp
Gonioscopy
Visual field
Fundus photographs
OCT
Ancillary tests
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2.6 Figures
Figure 2.1: OCT Image of a healthy retina19

Footnote: Morrison, J. C., & Pollack, I. P. (2003). Glaucoma: Science and practice. New York: Thieme
Medical Publishers.
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CHAPTER 3 The effectiveness of teleglaucoma versus in-person
examination (Systematic Review and Meta-Analysis)
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3.1 Introduction
Glaucoma is the leading cause of irreversible visual impairment in the world
affecting 60.5 million people worldwide in 2010, which is expected to increase to
approximately 79.6 million by 2020.1 Therefore, glaucoma screening is important to
detect, diagnose, and treat patients at the earlier stages to prevent disease progression
and vision loss. Teleglaucoma uses stereoscopic digital imaging to take ocular images,
which are transmitted electronically to an ocular specialist. Teleglaucoma involves
standardized equipment (Table 1). The purpose is to synthesize literature to evaluate
teleglaucoma, its diagnostic accuracy, healthcare system benefits, and costeffectiveness. This chapter has been recently published.2

3.2 Methods
3.2.1 Search Strategy

A search methodology was used to assist in locating both published and
unpublished studies. Research databases and conference meeting abstracts were
searched for articles published from 1999 to current, and included MEDLINE (OVID and
PubMed), Cochrane Library (Wiley), BIOSIS (Thomson-Reuters), CINAHL (EBSCO),
Web of Science (Thomson-Reuters), and EMBASE (OVID). The grey literature was
explored by searching Dissertations and Theses (ProQuest), the Canadian Health
Research Collection (Ebrary), as well as the annual meeting abstracts of the European
Society of Ophthalmology, Canadian Ophthalmology Society (COS), Association for
Research in Vision and Ophthalmology (ARVO), and American Academy of
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Ophthalmology (AAO). The Conference Proceedings Citation Index was also included
as part of the Web of Science search. Hand searches of ARVO’s Investigative
Ophthalmology & Visual Science journal and Canadian Journal of Ophthalmology
associated with COS were performed. The search strategies employed database
specific subject headings and keywords for glaucoma, tele-screening, detection, and
their synonyms. Each strategy was structured to accommodate for database and
platform specific terminology, and syntax. The appendix contains the complete search
strategies used for the various databases (Appendix 2). Alerts were set up for each
database to receive publication notifications for new related articles.

3.2.2 Inclusion and exclusion criteria

Articles included were from any country, all in English, published from 1999 to
current, and were research articles. The articles included a study population that
consisted of adults in the general population or populations at risk of glaucoma. The
study population included those with or without glaucoma. Articles on teleglaucoma
intervention for glaucoma screening were included, both in-comparison to in-person
screening and analyzing teleglaucoma on its own. Outcome measures of teleglaucoma
articles selected contained efficiency measures, specificity, sensitivity, and its ability to
detect glaucoma, as well as patient benefits and cost data. Economic evaluations such
as cost-effectiveness analysis and studies with costing data were also included.

Specificity of teleglaucoma for this study was defined as the proportion of nonglaucoma cases who were correctly detected by teleglaucoma as a negative screen
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test.3 Whereas, sensitivity of teleglaucoma was defined as the proportion of glaucoma
cases who were correctly detected by teleglaucoma as a positive screen test. 3 The
proportion of true positive and negative cases are given through the diagnostic tests
conducted by the ophthalmologist. Patients who were diagnosed by the
ophthalmologists as glaucoma-positive were considered “true positives” and the
patients who were diagnosed by the ophthalmologist as non-glaucoma cases were
considered “true-negatives”.

The exclusion criteria consisted of articles published prior to 1999 since
teleglaucoma is fairly new and to be consistent with the teleglaucoma screening
procedure, year 1999 was selected as a cut-off year. Additionally, non-research articles
such as methodology papers, editorials, review articles, commentaries, and letters were
excluded. Articles on diagnosis or prognosis, genetic screening, and teleophthalmology
for ocular conditions other than glaucoma were eliminated.

A total of 11,237 articles were retrieved by searching various databases and an
additional 526 were retrieved from hand searching and grey literature search, which
were then imported into EPPI 4.0 reference manager. Based on the inclusion and
exclusion criteria, two reviewers independently reviewed all articles. After removing
duplicate articles, 8157 articles were included for screening. Articles were screened by
title, abstract, and full text in level 1, 2, and 3 screening, respectively. After each level of
screening, kappa statistics was calculated to measure reviewer’s agreement.
Additionally, if consensus was not reached by the two reviewers;’ then a third reviewer
intervened to solve disagreements on article eligibility. The agreement between the two
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reviewers was excellent (kappa = 0.86). The PRISMA diagram demonstrating the
selection process is displayed in Figure 1.

3.2.3 Quality Assessment Strategy

Articles were assessed using the Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) guidelines for publication bias, risk of bias,
imprecision, inconsistency, and indirectness.4-9 Articles were graded as either low,
moderate, or high quality of evidence. The results indicated that 17 articles were high
quality, 13 were moderate quality, and 15 articles were graded as low quality of
evidence. Despite the quality of evidence, all articles were included in the analysis.

3.2.4 Data Extraction Strategy

Qualitative and quantitative data necessary for the analysis was obtained from
each article. Information on study location, design, effect measures (sensitivity and
specificity), percentage of glaucoma diagnosed, service times, image quality, visual
acuities, ophthalmic characteristics, and costs were collected. One reviewer extracted
data using an excel template. Authors were emailed to obtain missing relevant
information. All databases were updated with new information from respective authors.
Additional current costing data was provided by ophthalmic equipment vendors,
INNOVA, Topcon, and Ocular Health Network. Costs were converted to 2014 US
dollars.10-14 This research study has no financial relationships, investments, or
sponsorship related to the cited commercial vendors.
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3.2.5 Data Analysis

Data was synthesized and analyzed using STATA 13. When studies reported
estimates as a range or p-value or multiple estimates, mean and standard deviation
(SD) were derived. Hierarchical logistic regression was used to determine the pooled
estimates of sensitivity and specificity of teleglaucoma, and in-person examination.
Hierarchical modeling was used because it is appropriate for mixed models with grouplevel data.15 It incorporates both fixed-effects and random-effects models.16 The dataset
of this study consists of both within study variance and between study variance. Thus,
hierarchical logistic regression modelling would allow multilevel analysis.15,16 A graphical
representation of the summary estimates was presented in a Hierarchical Summary
Receiver Operator Characteristic (HSROC) curve with 95% confidence intervals and
95% prediction regions.

The positive/negative likelihood ratios (LR+/LR-) were calculated using bivariate
models to generate estimates of the likelihood of a positive/negative test in a
glaucoma/non-glaucoma patient. From this result the diagnostic odds ratio (DOR) was
calculated to determine the relative diagnostic effectiveness of teleglaucoma. DOR is
the ratio of the odds of a positive screen test in a glaucoma case relative to the odds of
a negative screen test in a non-glaucoma case.17

Due to the variability of study effectiveness measures, not one article had a
complete set of data. Missing data were missing completely at random.18 The data was
missing due to many reasons such as findings were not reported or the study objectives
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were different. Missing data were treated as statistically missing and was coded in the
dataset accordingly. This means that the missing values did not contribute to any
denominator counts or sample size counts. As a result, the missing data was not
included in the analysis. Only articles with complete data were included in each
analysis. Study heterogeneity was assessed statistically with the calculation of the Isquare.

3.3 Results
A total of 45 studies (101,512 participants) were included in this meta-analysis.
Table 3.2 and Table 3.3 display the baseline characteristics of each study. Studies were
conducted in 14 different countries with representation in each continent. All articles
were published between 1999 and 2014. All studies were observational studies, as
there were no randomized controlled trials conducted. Three studies contained
economic evaluations or cost-effectiveness analysis. Of the 45 studies, 16 compared
teleglaucoma to in-person examination. The other 29 studies analyzed teleglaucoma
without comparison or used an evaluation of different teleglaucoma equipment. There
was minimal variation in study populations; they included either glaucoma patients or
patients who were at risk of glaucoma (based on diabetes status, family history of
glaucoma, age, or ethnicity). Table 4 displays additional study details on demographics
and study methods (glaucoma definition, pupil dilation, and number of field tests
examined). Although there was some variation, less than 10% of studies reported these
details. The main outcome measures were specificity and sensitivity (Table 3.5). Other
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included outcome measures displayed in table 3.5 are: percentage of glaucoma
diagnosed, referral rate, and proportion of images with poor quality.

Costing data was given by nine studies and the quality of analysis of costing is
displayed in table 3.6. Teleglaucoma costs vary by the capacity of the service and the
type and amount of equipment. The current vendor estimate shows that the total costs
for standard glaucoma equipment range from 89,703.53 to 123,164.55 US dollars
(Table 3.6).11,12 Additionally, to transfer images and patient test results securely to
ophthalmologists electronically, a service exists costing $62.13 US/month.10,13 This
service allows teleglaucoma technicians and ophthalmologists to log-in electronically to
attach, send, view, and assess retinal images and patient test results.

There was a wide range of costing data reported in literature. To demonstrate the
distribution, the costing data from the literature shows the cost per detected case of
glaucoma ranged from $13.03 – 2020.96 US after conversion to US dollars and
adjusted for inflation to 2014 costs (Table 3.7).13 The range represents teleglaucoma
with minimal to optimal amount of resources. The lower range is represented by smaller
teleglaucoma services with one grader and one diagnostic instrument (tonometer). The
higher range represents a larger teleglaucoma service with a few graders, technicians,
and nurses, and the full set of ophthalmic instruments outlined in Table 3.1.The mean
cost is $1098.67 US for every case of glaucoma detected (n=3) (Table 3.7). The mean
cost of teleglaucoma per patient screened was $922.77 US (n=2) (Table 3.7).

44

Another necessary costing aspect is the ophthalmologist fee for glaucoma
consultation. The ophthalmologist may be compensated for each teleglaucoma referral
or time spent on teleophthalmology consultations. Compensation varies by states
and/or provinces, government legislation, and available private grants. In the United
States, Medicare and Medicaid provide several reimbursement programs for physicians
delivering telemedicine consultations.18,19 In Ontario, Canada, the compensation for the
fee-for service model, is $16.00 CAN per ophthalmic referral.20 The physician liable for
teleglaucoma consultations must be a licensed ophthalmologist in both the area of the
service and the patient. Physicians must hold liability coverage appropriate to
state/provincial laws. In Canada, the Canadian Medical Protective Association provides
ophthalmologists with liability coverage for teleophthalmology.21

Ten studies had complete data to be included for the analysis for teleglaucoma
diagnostic accuracy. The summary estimate for sensitivity was 0.833 [95% CI 0.77,
0.88] and specificity was 0.79 [95% CI 0.668, 0.875] for glaucoma screening using optic
nerve examinations (Appendix 3). The summary estimates indicate that teleglaucoma
correctly detects 83.3% of glaucoma cases and correctly classifies 79% of those without
glaucoma as glaucoma-negative. Figure 3 displays each study estimate and the
summary estimate with its associated confidence intervals and the generated HSROC
curve. The HSROC curve demonstrated a fairly narrow range which indicates that
changing the summary specificity moderately affects the summary sensitivity. The
HSROC curve was a positive upward slope indicating a positive relationship between
specificity and sensitivity; there is a positive trade-off between the two effectiveness

45

measures. The HSROC curve lies above the threshold, indicating the accuracy of
teleglaucoma is better than random chance. The HSROC curve appears in the left
upper quadrant and provides a large area under the curve. This is an important
measure of accuracy; because the area under the HSROC curve is large, this means
teleglaucoma is a relatively accurate screening device.

The distribution of the studies in the HSROC plot demonstrates the variability of
both specificity and sensitivity amongst studies. Six studies fall outside of the 95%
confidence interval of the summary estimate. The 95% prediction region is the estimate
of future observations. The results demonstrate a fairly wide prediction region for both
true predictions of specificity and sensitivity, with greater variability expected for
specificity.

The study populations used to assess diagnostic accuracy were those at-risk of
glaucoma (based on diabetes status, family history, age, ethnicity, etc.), optometrist and
ophthalmic clinic patients, and patients who were glaucoma suspects (Table 3.1). One
study reported its study population as glaucoma patients only (Table 3.1) and on the
contrary, this study had one of the lower reported scores for diagnostic accuracy:
specificity was 71.5% and sensitivity was 67% (Table 3.5).24

The diagnostic tools of the included studies varied slightly (Table 3.8). Eight out
of the ten studies analyzed for sensitivity and specificity used at minimum optic nerve
examinations as part of the screening process (Table 3.8). The other two studies
reported using IOP or visual field defects as the methods to detect glaucoma suspects
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(Table 3.8). For these studies which did not include fundus photographs, the sensitivity
and specificity were 81.5% and 95.5% respectively for glaucoma screening using only
visual field and 38.1% and 98.8% respectively for glaucoma screening using IOP and
Orbscan Topography (Table 3.5).25,26

Three studies reported sensitivity and specificity of in-person examination. The
weighted mean of sensitivity was 74.9 + 27.6% (n=3) and specificity was 88.8 + 10.3%
(n=3) for in-person examination. The summary estimates indicate that in-person
examination correctly detects 74.9% of glaucoma cases and correctly classifies 88.8%
of those without glaucoma as glaucoma-negative.

The positive likelihood ratio was 3.97 [95% CI: 2.3-6.7] while the negative
likelihood ratio was 0.21 [95% CI: 0.14-0.32] (Appendix 3). This demonstrates that the
likelihood of a positive screen test in a glaucoma case is greater than the likelihood of a
negative screen test in a non-glaucoma case. In addition, the positive likelihood ratio is
greater than one and thus the positive screen test is associated with glaucoma. Since
the negative likelihood ratio is less than one, the negative screen test is associated with
the absence of the disease.17 The effectiveness of the diagnostic accuracy of
teleglaucoma was given by the DOR, which was 18.7 [95% CI: 7.9-44.4] (Appendix 3).
The relative odds of a positive screen test in glaucoma cases are 18.7 times more likely
than a negative screen test in a non-glaucoma case. Since the DOR was greater than
one, the test is discriminating between true positives and true negatives correctly. 17
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There was insufficient data to conduct hierarchical logistic regression on the
percentage of glaucoma diagnosed. Three of the 45 studies reported percentage of
glaucoma diagnosed in both teleglaucoma and in-person examination necessary for
analysis. The mean percentage of glaucoma diagnosed was 13.4% for teleglaucoma
and 7.8% for in-person examination which suggests that teleglaucoma is capable of
detecting more cases of glaucoma.

Other effectiveness measures of teleglaucoma were analyzed such as variables
of healthcare service quality. The mean percentage of patients referred to a specialist
for consultation was 12.5 + 7.8% (n=6). The mean percentage of images that were of
poor quality was 10.4 + 6.7% (n=7). It took a mean time of 75.6 + 87.7 seconds (n=4) to
process the teleglaucoma images. Timing associated with teleglaucoma service is
another measure of quality. The mean time for screening was 8.8 + 5.1 minutes (n=3).
The time reported for an ophthalmologist to make a diagnosis was 34 minutes (n=1).
The mean reporting time was 7.6 + 2.6 minutes (n=6). Teleglaucoma gave a
reduction for patient travel time of 61.23 hours (n=1). Teleglaucoma had a mean access
time (time from patient being referred to the date visit is booked) of 59.7 + 9.9 minutes
(n=4) in comparison to 73.7 + 29.8 minutes (n=4) for in-person examination. The mean
cycle time (time from registration until patient leaves clinic) for teleglaucoma was 81.7 +
6 minutes (n=2), which was less than that of in-person examination, 116 + 2.5 minutes
(n=2). The mean proportion of patient satisfaction with teleglaucoma was 47.3 + 8.8%
(n=2) while only 42% (n=1) were satisfied with in-person examination.
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The heterogeneity amongst the studies was given by the I-square. The I-square
generated for specificity was 65.2% (p=0.05) and for sensitivity the I-square was 75.6%
(p=0.52). This indicates there is moderate heterogeneity (50-75%) between studies
regarding the specificity estimates.27 In addition, the I-square is statistically significant.
Thus, the variation between studies is statistically significant. This can bias the pooled
estimate for specificity. The I-square for sensitivity falls within the criteria for moderate
and substantial heterogeneity (>75% indicates substantial heterogeneity). 19,27 There
was substantial variation between studies regarding the sensitivity estimate. However,
the heterogeneity was not statistically significant (p>0.05). Thus, although there was
heterogeneity reported, it was not statistically significant. Consequently, this means
there was potential homogeneity rather than heterogeneity regarding the study
estimates for sensitivity.19 Homogeneity, similarity between studies, is beneficial to the
pooled estimate as it indicates a lack of bias.19

3.4 Discussion
Telemedicine has demonstrated good use for offering glaucoma services to
people of remote areas. Teleglaucoma is beneficial to remote areas as the physician is
not required to see patients in person, which reduces wait times and shortens the length
of ophthalmic consultations. Teleglaucoma avoids long distance travel and time wasted
on commute.

The results of the pooled estimates for diagnostic accuracy have shown
teleglaucoma to be less sensitive and more specific than in-person examinations.
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Teleglaucoma is advantageous at detecting true positive cases of glaucoma, but has a
higher rate of false positives in comparison to in-person examination. However, for
teleglaucoma screening it is more important to have a low level of false negatives. This
is because if cases of glaucoma are not detected, they are not treated. Without
treatment, glaucoma can progress to advanced stages unknowingly. This is significant
because as glaucoma progresses vision loss and visual defects become more severe
and more importantly, visual impairment due to glaucoma is permanent. Thus, a low
level of false negatives can avoid patients missing out on treatment. In addition, with
very high DOR estimates, it is suggested that teleglaucoma can accurately discriminate
screen tests.

Teleglaucoma has demonstrated capability to detect glaucoma cases that may
not have been detected during in-person examination. Glaucoma progresses without
patient awareness and it is usually detected at the advanced stages. Thus,
teleglaucoma serves as a tool for early detection of glaucoma. If caught earlier and with
treatment, glaucoma can be effectively managed and can result in the preservation of
vision.

Telemedicine for glaucoma can have several combinations of examinations and
measurements used for glaucoma screening. Examination of fundus photographs are
commonly used for teleglaucoma screening. Four of the ten studies analyzed used only
fundus examinations while another four studies included IOP, CCT, visual field loss, and
visual acuity, in addition to fundus photograph examinations (Table 8). Two studies did
not use fundus photograph examination, but rather visual acuity, IOP, CCT, and ACT
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(Table 8). However, this is based on studies who explicitly stated the terms for
ophthalmic examination. Some studies reported “comprehensive eye examinations”
were performed, but did not explicitly state which examinations were performed, thus
assumptions cannot be made. The use of different tests for glaucoma screening can
potentially bias the results as the more diagnostic tools used during screening results in
a greater probability of correct diagnosis naturally. However, the results did not show
any significant differences in accuracy with studies which reported using multiple
diagnostic tools. Interestingly, the specificity and sensitivity values reported ranged
independent of the number and the type of examination used for teleglaucoma (Table 4
and Table 8).

The combinations of examinations are dependent on financial and resource
limitations of the hosting organization and can vary from small programs to very large
programs. It is dependent on the target goals and target populations of the organization.
However, the standard examinations recommended for glaucoma screening are those
that can evaluate visual field defects, IOP, and the biological structure and function of
the optic nerve. These include HRT, OCT, optic disc photography, RNFL photography,
as well as FDT, tonometry, and perimetry.27

There were limitations within the study. Insufficient data reported was a major
limitation of the meta-analysis, although authors were contacted for additional
information. Nevertheless, the key goal was to systematically review the literature on
tele-glaucoma and in-person screening and perform the meta-analysis. With small
sample sizes there was not enough power to show statistical or clinical significance.
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Different comparators were reported by studies and to ensure internal validity, only
studies with exact comparators were analyzed together. This was one of the reasons for
reduced sample sizes for the analysis. However, our analysis does provide information
on diagnostic accuracy of teleglaucoma, its capability to detect glaucoma, and to detect
negative and positive cases correctly. It demonstrates teleglaucoma has the potential as
a screening device to detect a greater amount of cases than in-person examination.
Since teleglaucoma is an active screening, it suggests glaucoma cases are detected at
earlier stages. However the significance of this difference is limited by the number of
comparative studies. The majority of the studies were non-comparative which, in
addition, limits the significance of the relative effectiveness to in-person examination.

Teleglaucoma has been evaluated in many different ways: diagnostic accuracy,
cost reduction, technological capabilities (image quality, image transmission speed,
etc.), reduction of patient and health care provider time, and convenience. Thus many
studies focus on part of the effectiveness. As a result, there is insufficient data when
summarizing all of the studies together. This has proven the need for more research
literature on the diagnostic accuracy of teleglaucoma and its ability to detect glaucoma
in comparison to in-person examination. There is a need for research on the follow-up
of detected cases and long-term effects of teleglaucoma. In addition, better quality of
evidence through randomized controlled trials is recommended. There are implications
for cost-effectiveness analyses. Although, costing data suggests cost savings for
patients’ time and travel with teleglaucoma. Thus, a thorough costing of current health
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care expenditure is required to determine its overall cost-effectiveness from the scope
of the healthcare system.

Teleglaucoma is beneficial to offering services in underserviced regions and rural
areas. It considerably reduces patient access times and cycle times. The time required
for service is shorter than in-person examination and physician commitments are
reduced. As a result teleglaucoma saves costs to patients and costs to the health care
system as a whole.
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3.6 Tables
Table 3.1: Standardized Teleglaucoma Equipment
Components

Requirements

Human Resources

Staff: graders, Ophthalmic technicians, nurses, optometrist,
physicians, glaucoma specialists/ophthalmologists
Secure Diagnostic Imaging (SDI) system

Information Technology

Videoconferencing equipment
Computer systems and software
ISDN installation

Screening Equipment

Retinal camera
Tonometer
Devices to measure central corneal thickness
Frequency Doubling Technology (FDT) or Humphrey Visual
Field test
Optical Coherence Tomography
Slit lamp
Gonioscope
Retinal camera
Tonometer
Devices to measure central corneal thickness

Examinations

Medical & family history
Visual acuity
IOP
CCT
Pupil equal and reactive to light (PERL) or relative afferent
pupillary defect (RAPD)
Slit lamp
Gonioscopy
Visual field
Fundus photographs
OCT

59

Ancillary tests
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.2: Baseline Characteristics of Included Studies - Demographics
Author (Year)
Tuulonen et al.
(1999)23
Eikelboom et
al. (1999)19
Li et al.
(1999)24

Location

Study
Design

Sample
Size

Finland

PC

70

Glaucoma patients

Australia

PC

27

Glaucoma patients

USA

PC

32

PC

27

PC

10

Diabetic adults
Glaucoma clinic
patients/suspected of
glaucoma
Glaucoma-diagnosed
patients

PC

14

Ophthalmic Clinic patients

PC

43

Ophthalmic Clinic patients

PC

139

Ophthalmic Clinic patients

CS

74

Glaucoma suspects

PC

1733

PC

1205

PC

33

CEA

339

PC

113

PC

1729

PC

33

PC

348

PC

107

PC

201

CS

30

PC

350

PC

28

Yogesan et al.
(1999)25
Australia
Michelson et
al. (2000)26
Germany
Yogesan et al.
(2000)27
Indonesia
Yogesan et al.
(2000)28
Australia
Gonzalez et al.
( 2001)29
Spain
Sebastian et
al. (2001)30
Spain
Wegner et al.
(2003)31
Germany
Labiris et al.
(2003)32
Greece
Fansi et al.
(2003)33
Canada
Jin et al.
(2003)34
Canada
Chen et al.
(2004)35
Taiwan
de Mul et al.
(2004)36
Netherlands
Ianchulev et al.
(2005)20
USA
Paul et al.
(2006)37
India
Kumar et al.
(2006)21
Australia
Kumar et al.
New
38
(2007)
Zealand
Khouri et al.
(2007)39
Not Stated
Pasquale et
al. (2007)40
USA
Khouri et al.
(2008)41
USA

Population

Not stated
Glaucoma-diagnosed
patients
Glaucoma suspects or
diagnosed
Diabetic aboriginals
Residents of area aged >
40 years
Optometrist patients atrisk for glaucoma
Glaucoma suspects or
diagnosed
Rural residents at risk for
glaucoma
Patients of the Eye Clinic
General eye examination
clinic Patients
Glaucoma-diagnosed
patients
Diabetic
Glaucoma-diagnosed
patients
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deBont et al.
(2008)42
Sogbesan et
al. (2010)43
Anton-Lopez
et al. (2011)44
Khurana et al.
(2011)45
Staffieri et al.
(2011)46
Swierk et al.
(2011)47
Amin et al.
(2012)48
Shahid et al.
(2012)49
Kassam et al.
(2012)50
Gupta et al.
(2013)51
Damji et al.
(2013)52
Kiage et al.
(2013)53
Verma et al.
(2013)54
Ahmed et al.
(2013)55

Optometrist patients atrisk for glaucoma
Optometrist patients atrisk for glaucoma

USA

PC

1729

Canada

CEA/PC

--

Spain

CS

1599

At-risk for glaucoma

India

CS

91698

Tasmania

PC

133

Ophthalmic Clinic patients
High risk (First degree
relatives of diagnosed
POAG)

Germany

EE

--

Canada

PC

72

USA

CS

341

Canada

PC

257

Ophthalmic Clinic patients
Glaucoma suspects or
early stages of OAG
Urban soup
kitchen/homeless
At-risk for glaucoma or
early-stage glaucoma

India

PC

247

Ophthalmic Clinic patients

Canada

PC

71

Ophthalmic Clinic patients

rural Africa

PC

309

Canada

RC

247

Diabetic adults
Optometrist-referred
glaucoma suspects or
early OAG

USA

RC

643

Diabetic and hypertensive
Glaucoma clinic
Arora et al.
patients/suspected of
56
(2014)
Alberta
PC
71
glaucoma
Legend: CS = Cross-Sectional Study, PC = Prospective Cohort Study, CEA = Costeffectiveness Analysis, RCS = Retrospective Cohort Study, EE = Economic
Evaluation, -- = Not Stated
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.3: Baseline Characteristics of Included Studies - Intervention
Author (Year)
Tuulonen et al.
(1999)23
Eikelboom et al.
(1999)19

Teleglaucoma Equipment
Canon CR5-45NM non-mydriatic fundus camera, slitlamp, Panasonic video camera, HF II perimeter

Li et al. (1999)24
Yogesan et al.
(1999)27
Michelson et al.
(2000)26
Yogesan et al.
(2000)27

Non-mydriatic retinal camera. Digital images

Yogesan et al.
(2000)28
Gonzalez et al. (
2001)29
Sebastian et al.
(2001)30
Wegner et al.
(2003)31
Labiris et al.
(2003)32
Fansi et al.
(2003)33
Jin et al. (2003)34
Chen et al.
(2004)35
de Mul et al.
(2004)36
Ianchulev et al.
(2005)20

Nidek Nm-100 Handheld fundus camera

Portable fundus camera, Nidek NM100
Self-tonometry portable device called Ocuton,
PalPilot, IOP curve
Handheld fundus camera (NM100)
DIO digital indirect ophthalmoscope, handheld fundus
camera Nidek NM100, stereo fundus camera ( Nidek
3D-x)
Non-mydriatic fundus camera (canon CR6-45M)
C-20-5 FDT, Humphrey-Zeiss, & Topcon optic nerve
head photographs
Goldman applanation tonometer and mobile HRT
Slit lamp, Octapus perimeter visual field, fundus
camera, Optotype, air tonometer

-Tonometry
Digital 35-degree colour fundus images, nonmydriatic digital fundus camera (CR6-45, Canon)
Nerve fibre analyser, GDx
Peristat: self-test
--

Paul et al. (2006)37
Kumar et al.
(2006)21
Kumar et al.
(2007)38

--

Khouri et al.
(2007)39
Pasquale et al.

Digital stereo fundus camera - Nidek 3-Dx
Topcon TRC NW-5S non-mydriatic retinal camera

I-care tonometry

Comparator
In-person
examination
Teleglaucoma
only
Image Quality
of
Teleglaucoma
Teleglaucoma
only
Teleglaucoma
only
Teleglaucoma
only
Teleglaucoma
only
In-person
examination
Teleglaucoma
only
Teleglaucoma
only
In-person
examination
Healthy vs
Glaucoma
eyes
In-person
examination
In-person
examination
In-person
examination
In-person
examination
Teleglaucoma
only
Teleglaucoma
only
In-person
examination
Image Quality
of
Teleglaucoma
Teleglaucoma
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Author (Year)
(2007)40

Teleglaucoma Equipment
(Paramus) interfaced to a standard color video
camera (Sony 970-MD)

Khouri et al.
(2008)41

Non-mydriatic 45-deg camera, Canon Japan. DICOM
image format

deBont et al.
(2008)42

Nerve fibre analyser, GDx

Sogbesan (2010)43
Anton-Lopez et al.
(2011)44
Khurana et al.
(2011)45
Staffieri et al.
(2011)46
Swierk et al.
(2011)47
Amin et al. (2012)48
Shahid et al.
(2012)49
Kassam et al.
(2012)50
Gupta et al.
(2013)51
Damji et al.
(2013)52
Kiage et al.
(2013)53
Verma et al.
(2013)54
Ahmed et al.
(2013)55
Arora et al.
(2014)56

-HRT, nerve-fibre analyzer (GDX-VCC), I-Care
(rebound tonometry)
---Slit lamp, IOP, CCT, visual field, anterior and stereo
posterior segment photos and OCT
8.2 megapixel non-mydriatic retinal camera
Remote service - slit lamp, fundus photographs,
Fundus Camera (Portcam II)
-Topcon 777
-Topcon TRC non-mydriatic retinal camera, Tonopen
--

Comparator
only
Image Quality
of
Teleglaucoma
Image Quality
of
Teleglaucoma
In-person
examination
In-person
examination
Teleglaucoma
only
Teleglaucoma
only
In-person
examination
In-person
examination
Teleglaucoma
only
In-person
examination
In-person
examination
In-person
examination
In-person
examination
In-person
examination
Teleglaucoma
only
In-person
examination

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.4: Additional Details on Baseline Characteristics of Included Studies

Study Population
Ethnicity

Glaucoma definition

Eikelboom et al.
19
(1999)

–‒

–‒

Yogesan et al.
25
(1999)

–‒

–‒

Yogesan et al.
27
(2000)

–‒

–‒

Yogesan et al.
28
(2000)

–‒

–‒

Ianchulev et al.
20
(2005)

15% White, 9%
African American,
76% Hispanic

–‒

Author (Year)

Chen et al.
(2004)

(2006)

21

Paul et al.
(2006)

Yes
Yes
Yes
Yes

–‒
–‒
–‒
–‒
–‒

No

100% Asian

"The diagnosis of glaucoma was made
according to the anatomical findings
from the patient’s optic nerve disc, and
functional visual field examination by
frequency-doubling perimetry (FDP).
Intraocular pressure (IOP) was also
evaluated. An elevated IOP was
defined as over 17mmHg (1mmH = 133
Pa). Severe glaucoma was defined as
an optic cup: disc ratio over 0.7 with an
FDP defect or elevated IOP. Mild
glaucoma was defined as an optic cup:
disc ratio between 0.7 and 0.5, or disc
asymmetry of over 20%, with an FDP
defect or elevated IOP."

–‒

–‒

96% Caucasian,
4% Asian

IOP of 21 mmHg was threshold for
suspected glaucoma

–‒

–‒

–‒

–‒

35

Kumar et al.

Dilated
pupil

#
Field
tests

100% Indian

–‒

37

Kumar et al.

–‒

In accordance with glaucoma
screening protocol of Lions Eye

–‒
Yes
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Author (Year)
(2007)

Study Population
Ethnicity

38

Pasquale et al.
40
(2007)

Staffieri et al.
46
(2011)

16% African
American (of
glaucoma
suspects) 14%
African American
(Of non-glaucoma
suspects)

–‒

Glaucoma definition
Institute: Vertical cup disc ratio (VCDR)
>0.5, IOP>21 mmHg, abnormal visual
field related to glaucoma, and or disk
asymmetry >0.2.
“VFs were considered glaucomatous if
the pattern deviation plot showed a
nasal step, nasal depression, arcuate
defect, paracentral loss that respected
the horizontal meridian, or temporal
wedge defects based on previously
published criteria... Patients were
designated as “no glaucoma” if the
CDR was "<0.6 in both eyes and CDR
asymmetry was < 0.1 in the absence of
reliable glaucomatous VFs. Patients
were designated as having “glaucomasuspicious optic discs” if the CDR was
"> 0.6 in either eye or CDR asymmetry
was > 0.1 with or without reliable
glaucomatous VFs. Patients with more
subtle optic nerve changes were
labeled as having glaucoma-suspicious
optic discs if VFs were available and
reliable and showed change consistent
with glaucomatous loss."
"Subjects were classified as having
definite glaucoma on the basis of
characteristic optic nerve head
changes (cup: disc ratio [CDR] outside
the 97.5 percentile for the normal
population or rim width less than 0.1
CDR at the superior and inferior poles
of the disc) and definite visual field
defect consistent with glaucoma.
Individuals with stereoscopic disc
photos consistent with structural
damage but in whom field testing was
unreliable or unobtainable were
classified as glaucoma suspect."

Dilated
pupil

#
Field
tests

–‒

Three

–‒

Yes
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Author (Year)
Khurana et al.
45
(2011)
Anton-Lopez et
44
al. (2011)

Shahid et al.
(2012)

49

Kiage et al.
(2013)

100% Indian
–‒

78% African
American, 10%
Caucasian, 6.7%
Hispanic, 4.8%
Other
100% African

53

Gupta et al.
(2013)

Study Population
Ethnicity

51

100% Indian

Glaucoma definition

Dilated
pupil

#
Field
tests

–‒

–‒

–‒

"2/3 Criteria were considered suspects
and referred for glaucoma consultation:
(1) global Moorefield’s Regression
Analysis borderline or outside normal
limits, (2) Nerve Fibre Index >30, and
tonometry >21mmHg."

–‒

–‒

Yes

One

Yes

Three

–‒

Category 1 diagnosis (structural and
functional evidence): 2 out of 3 of the
following: VCDR >0.7, focal glaucoma
disc changes, VCDR asymmetry (>
0.2). Category 2 diagnosis (structural
evidence with unproved field loss): 2
out of 3 of the following: VCDR >0.8,
focal glaucoma disc changes, VCDR
asymmetry > 0.3. Category 3 diagnosis
(optic disc not clearly seen): 1 of the
following visual acuity < 3/60 and IOP >
21 mmHg or visual acuity < 3/60 and
evidence of glaucoma surgery or
medical records confirming glaucoma
morbidity. Glaucoma suspect: one of
the following IOP > 23 mmHg, 1/3 of
the glaucomatous optic neuropathy
listed in category 2, glaucoma visual
field defect only.
Glaucoma diagnosis based on disc
findings VCDR of > 0.7 or focal
neuroretinal rim defect.

–‒
Yes

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.5: Study Relevant Outcome Measures

Specificity
(%)

Sensitivity
(%)

Percentag
e
Glaucoma
diagnosed

Li et al. (1999)24

–‒

–‒

–‒

–‒

18.8

Yogesan et al.
(1999)25

–‒

–‒

–‒

84.5

82.5

Eikelboom et al.
(1999)19

–‒

–‒

–‒

71.5

67

–‒

–‒

–‒

87

100

Gonzalez et
al.(2001)29

–‒

–‒

Sebastian et al.
(2001)30

–‒

Wegner et al.
(2003)31

–‒

Author (Year)

Yogesan et al.
(2000)28

de Mul et al.
(2004)36

Percentag
e Referral
Rate

Percentage
of Image of
Poor Quality

–‒
7.9

–‒

13

–‒
2.7

–‒

4

–‒
9.4

–‒
58

82

Ianchulev et al.
(2005)20

95.5

81.5

Kumar et al.
(2006)21

98.8

38.1

Kumar et al.
(2007)38

93.6

91.1

Pasquale et al.
40
(2007)

96

59

deBont et al.
(2008)42

–‒

–‒

Staffieri et al.
(2011)46

–‒

4.6

11

–‒

–‒

–‒

–‒

–‒

–‒

–‒

–‒

–‒

–‒

–‒

–‒

11

11

–‒

–‒

–‒

–‒
5

68

Anton-Lopez et
al. (2011)44

–‒

Khurana et al.
(2011)45

–‒

Shahid et al.
(2012)49

–‒

Ahmed et al.
(2013)55

–‒

–‒

–‒
1.9

7.7

–‒

–‒
1.06

12.5

–‒

–‒
32

–‒

–‒
–‒

Gupta et al.
(2013)51

81.82

72.1

Kiage et al.
(2013)53

89.6

41.3

Verma et al.
(2013)54

–‒

–‒

Arora et al.
(2014)56

–‒

19.4

5

–‒

–‒

–‒
14
31

–‒

24
31

–‒

–‒

44

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.6: Quality of Analysis for Costing

Author
(Year)

Object

Tuulonen
et al.
(1999)23

Fixed Costs

Costs ($)

Currency

Fundus camera (1 unit)

200

FIM

ISDN installation (3 units)

6.5

FIM

Server computer (2 units for 5
years)

50

Software application (2 units for
5yrs)

50

Video slit-lamp (1 unit)

40

FIM

Write off 10 years (3%)

40.62

FIM

Use of teleophthalmology
equipment

24.372

Video conference equipment

FIM
FIM

FIM

84

FIM

18.342

FIM

132

FIM

15.474

FIM

Service and updating

5

FIM

Line costs per month

3.672

FIM

Premise

1.608

FIM

Utilities

1.608

FIM

Other costs

7.133

FIM

Satellite phone

30000

EUR

Write-off 5 years
Automated perimetry – Humphrey
Write off 10 years (3%)
Other fixed costs

Yogesan
et al.

70

Author
(Year)

Object

Costs ($)

Currency

3250

EUR

Total expenditure capital

160260

CAN

Operating costs per 1 year

348665

CAN

Projected 2005 Costs

385226

CAN

Operating costs amortized over 5
years

32052

CAN

Operating costs amortized over 5
years per diabetic case

1231

CAN

Professional and Lab Fees

291

CAN

Costs per patient

1231

CAN

Travel costs

805

CAN

Escort travel expenses

340

CAN

(2004)35

Costs per detected case

10

US

Ianchulev
et al.
(2005)20

Costs per targeted glaucoma
screening

60

US

Costs per detected case

1000

US

Patient savings

2527

CAN

24150

EUR

1420

EUR

(2000)27
Mobile phone
Jin et al.
(2003)34

Chen et al.

Sogbesan
(2010)43

AntonLopez et
al. (2011)44 Incremental Costs
Costs per detected case
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Author
(Year)

Object

Costs ($)

Currency

Primary Care visit

15

EUR

General Ophthalmic Visit

18

EUR

Ophthalmic Visit with tests

52

EUR

Glaucoma Consultation

26

EUR

291.21

EUR

280

EUR

Costs per patient

288.72

EUR

Equipment costs (digital retinal
camera, Tonopen and computer)

46000

US

48,000 –
49,000

CAN

7,420 19,990

CAN

1,400 –
2,400

CAN

8,995

CAN

Retinal Camera

27,900 –
27, 995

CAN

Visual Field Analyser

16,340 –
32,420

CAN

Swierk et
al.
(2011)47

Medical Care
Accommodation costs

Ahmed et
al.
(2013)

55

Vendor
Estimates
(2014)10, 11

OCT
Slit Lamp

Tonometer
Slit lamp mounted
Non-contact

72

Author
(Year)

Object

Costs ($)

Currency

89,703.53
TOTAL RANGE: 123,164.55

US

Ocular
Health
Network
(2014)12

Imaging Transfer Service

70/Month

CAN

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779

Table 3.7: Teleglaucoma Estimated 2014 Unit Costs

Author (Year)
Jin et al. (2003)34

Cost per
detected case
($US)
(Adjusted for
inflation to
2014 costs)

Inflation
Rate
(%)

Cost per
patient
($US)
(Adjusted
for inflation
to 2014
costs)

Inflation
Rate
(%)

–‒

–‒

1434.63

25.49

13.03

30.32

–‒

–‒

Ianchulev et al.
(2005)20

1262.02

26.2

–‒

–‒

Anton-Lopez et al.
(2011)44

2020.96

5.89

–‒

–‒

Swierk et al.
(2011)47

–‒

–‒

410.91

5.89

Mean costs

1098.67

Chen et al.
(2004)35

922.77

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Table 3.8: Study Ophthalmic Examinations

Author (Year)

Examination tests

Li et al. (1999)24

Optic disc photographs, VCDR

Yogesan et al. (1999)25

VCDR

Eikelboom et al. (1999)19

VCDR

Yogesan et al. (2000)28

Fundus images, H/VCDR, radial rim measurements

Gonzalez et al.(2001)29

Fundus images

Sebastian et al. (2001)30

Visual acuity, IOP, FDT, optic nerve head
photographs

Wegner et al. (2003)31

HRT, IOP, OCT

de Mul et al. (2004)36

IOP, nerve fibre indicators

Ianchulev et al. (2005)20

HVF, visual acuity
IOP, CCT, ACT

Kumar et al. (2006)21
Kumar et al. (2007)38

IOP, FDT, VCDR, disc asymmetry, visual field,
fundus photographs

Pasquale et al. (2007)40

IOP, CDR, Humphrey visual field, comprehensive
eye examination

deBont et al. (2008)42

Nerve fiber indicators, fundus photographs, IOP

Staffieri et al. (2011)46

Visual acuity, refractive status, visual field testing,
IOP, CCT, stereoscopic optic disc photographs

Anton-Lopez et al.
(2011)44

IOP, HRT, nerve fibre indicators

Khurana et al. (2011)45

--

Shahid et al. (2012)49

IOP, optic nerve head appearance and asymmetry,
nerve fibre layer dropouts

Ahmed et al. (2013)55

Fundus images, CDR, IOP

Gupta et al. (2013)51

Fundus photographs
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Kiage et al. (2013)

53

Verma et al. (2013)
Arora et al. (2014)

54

56

Slit lamp examination, focal glaucoma damage,
VCDR, IOP, FDT, fundus images, visual fields
Stereoscopic optic nerve images, visual fields,
ancillary tests, IOP, OCT, and HRT
OCT, HRT, stereo-nerve photographs, FDT, HVF,
OCT, IOP

Legend: VCDR= vertical cup-to-disc ratio, HCDR= horizontal cup-to-disc ratio,
IOP= intraocular pressure, FDT= frequency doubling technology, CCT= central
corneal thickness, HRT= Heidelberg Retinal Tomography, CDR=cup-to-disc
ratio, HVF= Humphrey Visual Field, ACT= anterior chamber depth, POAG=
primary open angle glaucoma, OAG= open angle glaucoma
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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3.7 Figures
Figure 3.1: PRISMA Diagram

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Figure 3.2: HSROC Curve

Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779
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Chapter 4 The cost-effectiveness of teleglaucoma versus inperson examination

78

4.1 Introduction
The burden of vision loss on the Canadian economy is $15.8 billion per
year in which 55% is allocated to direct health care costs.1 Sixty-five per cent of
adults with partial or full vision loss are unemployed, which translates to $4.06
CAN billion annually of lost earnings.1 In the United States, vision loss costs over
$35 billion for direct costs and loss of productivity.2 Glaucoma is the major eye
disease leading to irreversible vision loss. The economic burden of glaucoma
alone on the American economy is $2.9 billion.2
Screening for glaucoma is important. Glaucoma is a public health concern.
It has a prolonged asymptomatic phase and if detected early and with effective
therapy blindness can be prevented.3 Screening has shown to be effective
specifically in high-risk populations such as patients older than 50 years and
black populations.3,4 Currently, screening for glaucoma occurs passively within
routine ocular examination at the optometrist and/or ophthalmologist clinics. This
is referred to as “in-person examination.”5,6 “Passive” screening is when the
patients come to the doctor and “active screening” is when the healthcare
providers actively draw patients in for screening. Active screening on a
population base, where health care providers provide outreach programs to draw
patients in for screening, rarely occurs.5 Mainly research or community groups
conduct population-based screening sporadically and there is no mandated
active screening that occurs at a population level.5 There are two main obstacles
with population-based screening: firstly, there is a lack of an efficient screening
test and secondly, there is insufficient economic evidence.5
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Teleglaucoma is an innovative screening test that has the potential to be a
sufficient screening tool. Chapter three of this thesis discussed the effectiveness
of teleglaucoma and found implementation of teleglaucoma improved the
detection of glaucoma on a population level. It was reported by Tuulonen et al
that patients were satisfied with teleglaucoma service as it successfully reduced
patient costs by 92%, saved patient time by 92%, and there was a 97% reduction
in patient travel.7 A recent study by Thomas et al synthesized the effectiveness of
teleglaucoma and found teleglaucoma was effective at screening negative
cases.8 The technology gave poor quality images in only 10.4% of images. 8 It
improved access to ophthalmologist and had a referral rate of 12.5% to the
ophthalmologist.8 This chapter will discuss the economic evidence of
teleglaucoma’s effectiveness and the objective is to determine the costeffectiveness of teleglaucoma as a screening device for glaucoma in comparison
to in-person examination.
Vision impairment associated with glaucoma negatively affects one’s
Health-Related Quality of life (HRQoL). Preference-based HRQoL is referred to
as the individual’s perception of his/her disease state and its effect on his/her
quality of life.9 HRQoL can be quantified using utility values which range from 0
indicating death to 1 indicating excellent health with complete functioning. 9
Therefore, glaucoma patients are hypothesized to have a lower utility value and
HRQoL than healthy people.
For cost-effectiveness analysis it is necessary to translate effect data into
Quality Adjusted life Years (QALYs) to allow easy comparison between different
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interventions. QALY incorporates both quality and quantity of life, specifically life
expectancy and quality of remaining life years.9,10 QALYs are the amount of
years in a person’s life that is adjusted to represent remaining life years in perfect
quality.9,10 It weighs the time spent in different health states. Consequently,
teleglaucoma has shown increased ability to detect glaucoma in rural Alberta,
allowing for treatment of cases in remote areas that would have not necessarily
be treated. In addition, it allows early detection of glaucoma to delay the
progression of disease. Thus, it is suggested that teleglaucoma increases
patients’ utility values, improves their HRQoL, and provides more QALYs
compared to standard in-person care.8
With implementation of any new technology and service comes an
additional cost. Thomas et al reported that teleglaucoma had a mean cost per
patient screened of $922.77 (US) and a mean cost per detected case of
$1098.67 (US).8 However, there are no economic evaluations in literature which
examine the cost-effectiveness of the use of telemedicine for glaucoma
screening. Thus, the purpose of this cost-effectiveness analysis (CEA) was to
examine the costs and benefits of teleglaucoma and to determine the costeffectiveness of teleglaucoma as a screening device for glaucoma in comparison
to the standard of care, which is in-person examination. This CEA took a thirdparty payer and Ministry of Health perspective. The targeted population included
people living in rural Alberta who are at-risk of glaucoma. The long term benefits
of teleglaucoma which included prevention of blindness from glaucoma was also
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assessed. A portion of this chapter has been conditionally accepted for
publication and is currently under second review.11

4.2 Methods
4.2.1 Study Design
A cost-effectiveness analysis was conducted using healthcare provider
perspectives within rural Alberta, Canada.11 Statistics Canada defines rural
populations as areas with persons living outside centers with a population of
10,000 or fewer and outside areas with fewer than 400 persons per square
kilometre.12 Other than certain parts of Edmonton and Calgary, the majority of
communities in Alberta are rural areas. It has been documented that 95% of
Alberta is rural area.13 The study population are patients at-risk of glaucoma,
which includes those with diabetes and/or hypertension, family history of
glaucoma, older adults, and concurrent ocular conditions in rural Alberta.
Targeting at-risk populations has been suggested as a more efficient method of
detecting glaucoma.14 Teleglaucoma screening in the model was applied to a
population aged 50 years and older at a frequency of one screening per year.11
The model assumed teleglaucoma has the capacity for 300 people per year. 7,11
The time horizon was 30 years as glaucoma is a chronic, life-long condition.
4.2.2 Teleglaucoma Definition
There are several standardized characteristics of Teleglaucoma (Table 1).
Teleglaucoma consists of standard ophthalmic instruments used for screening.
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The main instruments are the fundus cameras, Heidelberg Retina Tomograph
(HRT), and the optical coherence tomography (OCT), which produce digital
imaging of the retina.15-17 In addition, tonometers are used to measure the
intraocular pressure. Gonioscopy, a test used to determine the angle between
the iris and cornea, and perimetry, the visual field test, are also used for
teleglaucoma screening. The retinal images and test results are sent via
electronic systems. Thus, the essential part of teleglaucoma is the information
systems which include the Secure Diagnostic Imaging (SDI) systems, ISDN
installations, computers, and videoconferencing equipment. These equipment
would be set up within a small clinic in the vicinity of the rural population.
Teleglaucoma requires at minimum technicians who are trained to screen
the patients and to transfer the files to the ophthalmologist.7,15 The teleglaucoma
process is a quick process; the mean screening time is 8.8 minutes.17 Once the
images are sent to the ophthalmologist, the images and test results are then
used for diagnosis. If the patient is diagnosed or determined as a glaucoma
suspect, the patient is then referred to the ophthalmologist for a full consultation
and receives the standard of care for glaucoma treatment.
4.2.3 Comparator Definition
The comparator for this study was in-person examination, the standard
screening that occurs at the optometrists and/or ophthalmologists office. This
type of screening is a more “passive” type of screening where patients have their
routine eye examination; it is not necessarily a targeted screening for glaucoma.
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However, patients with known risk-factors for glaucoma are screened specifically
for glaucoma.
In-person examination uses the standard diagnostic instruments as
described for teleglaucoma with the exception of the imaging transferring
software.5,15 The staff required are optometrists, technicians, and
ophthalmologists.8,15 For in-person examination, the patient visits the optometrist
in person at the clinic for a full examination of the eye. If glaucoma is suspected
the patient is then referred to an ophthalmologist. The ophthalmologists will
perform several more diagnostic tests to diagnose glaucoma. Based on the
diagnosis, the patient will receive treatment in accordance with the standard of
care for glaucoma. If glaucoma is suspected the patient will continue to be
monitored by the ophthalmologists.6 For this study, in-person examination was
considered “no-screening or passive screening” intervention. It is also the “donothing” approach as it is the standard of care for glaucoma screening.
4.2.4 Markov Model
Markov Modelling was used to model the four glaucoma health states
(mild, moderate, severe, and blind).11 TreeAge Pro 2009 was used to build the
Markov Model (Appendix 4) consisting of the costs, benefits, and transitional
probabilities of different health states. Incremental cost-effectiveness ratios
(ICER) were developed in dollars per QALYs. Effectiveness was measured in
QALYs and costs were used in Canadian dollars. The cycle for the Markov Model
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represented one year and the ICERs following 30 cycles were established. 11
Assumptions that were used in the model is that:


Individuals with glaucoma who were screened negative with teleglaucoma
were assumed to be detected at the same probability of at-risk
populations. They will have the same probabilities as being detected
through in-person care.



Individuals without glaucoma who were correctly screened negative can
either remain at risk or transition to mild glaucoma at the transitional
probability without treatment.



Individuals with glaucoma who were seen by in-person care who were
incorrectly detected as negative for glaucoma were assumed to have
transitional probabilities based on untreated glaucoma.
In application, the implementation of teleglaucoma does not replace in-

person care, but rather is additional to in-person care. Thus, the teleglaucoma
arm of the decision tree, is displayed with combined costs and effect data of
teleglaucoma and in-person care (Appendix 4). This model provides an overall
outlook on total costs to run both programs at the same time in comparison to inperson examination.
4.2.5 Health States
There are four health states associated with glaucoma: mild, moderate,
severe, and end-stage glaucoma, which is blindness.6,18 Mild glaucoma is
characterized by abnormalities of the optic nerve without any visual field
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abnormalities. Moderate glaucoma is characterized by damage to the optic nerve
and some peripheral vision loss. Severe glaucoma is the advanced stage of
glaucoma characterized by severe optic nerve damage and advanced peripheral
vision loss.11 Blindness is characterized by a visual acuity of 20/200 or worst.19
Blindness in this study refers only to blindness due to glaucoma as opposed to
blindness due to other causes.
Glaucoma is a chronic condition with progressive ocular damage and
vision loss. Patients will progress from one stage to the next and with successful
treatments the patient will remain in the current health state. There is no cure for
glaucoma and thus patients cannot transition to healthier states. Once a patient
is blind, the patient will remain blind.
The Markov Model transitional states can be found in Figure 4.1. The
progression of glaucoma through the health states are at higher probabilities
when glaucoma is not detected early, not diagnosed, and/or left untreated (Table
4.2). The transitional probabilities are not time-dependent but rather depend on
management of disease through treatments or no treatments.9 If managed
appropriately with proper medications and treatment the progression of glaucoma
is delayed.6 Patients who were detected positive with either teleglaucoma or inperson care were assumed to be treated. There was a 75% compliance with
treatment and treatment efficacy was 50% as reported by literature. 9 Because
the progression of glaucoma is dependent on individual characteristics and
compliance to treatment, there is a degree of uncertainty with the transitional
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probabilities. As a result, beta distributions will be applied to transitional
probabilities and assessed through Probabilistic Sensitivity Analysis.
4.2.6 Costs
Technology Costs
There are three main components of teleglaucoma and each are associated
with costs: human resources, information technology, and diagnostic equipment
(Table 4.1).15 The synthesis of teleglaucoma costs derived by Thomas et al. and
the Ministry of Health Medical Procedures List were used as costing data
sources.17,21 Additional base costs of the teleglaucoma technology were
reported by a study on effectiveness of tele-ophthalmology for glaucoma by
Tuulonen.7 All costs were converted to 2014 Canadian dollars and adjusted for
inflation at 2.05%.17, Future costs were discounted at a 3% rate.9,10
Costs were divided by the number of patients serviced to determine the costs
per patient and also to account for the differences in coverage between in-person
care and teleglaucoma. Teleglaucoma was reported to service 300 people per
year, while in-person care was reported to have 1379 glaucoma visits per year in
rural Alberta.7,22 Teleglaucoma requires training of graders on how to use the
technology. The costs for training includes labour costs for two (full-time
equivalents) trainers at the average Alberta salary ($50,000) and training
resources.23 Costs assumed a maximum two week training session and paid for
trainees. The direct costs of teleglaucoma included the costs of equipment, setup, overhead, utilities, and labour (Table 4.3).
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Health State Costs
There are costs associated with living with glaucoma. Each health state
requires different levels of medical treatments and drug therapies. In addition,
each is associated with indirect costs such as health system costs, loss of
productivity, additional vision aids, and modifications to home or work to
compensate for vision loss. The costs associated with each health state was
given by Lee et al study on resource consumption at different levels of severity of
glaucoma.23 All stages include the following direct costs: visits to
ophthalmologists and/or optometrists, Humphrey Visual Field tests, medications,
surgeries, and glaucoma testing (gonioscopies, nerve fiber thickness analysis
and intraocular pressure diurnal).24
The stage at-risk was assumed to be equal to “Stage 0” of Lee’s criteria
which constitutes a glaucoma suspect patient who is at-risk of glaucoma, but
does not meet the criteria for clinical diagnosis.24 The costs associated with the
“at-risk” stage includes routine optometrists and/or ophthalmologist visits. The
costs of blindness were reported by the Canadian National Institute for the Blind
(CNIB).25 The costs of blindness includes direct costs (vision aids and
treatments) as well as indirect costs such as loss of productivity, caregiving
assistance, etc. Table 4 summarizes the costs associated with each health state.
The costs were derived to represent Alberta. In rural Alberta, there are limited
nearby ophthalmic resources and travelling when blind becomes a costly
endeavor.13,22 Thus, uncertainty in costs of blindness was addressed using
sensitivity analysis.
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Patient Costs
Teleglaucoma has been reported to have direct reduction in costs to patients
specifically in travel time, doctor wait times, assessment times, and
transportation costs.7,17,26 These costs were added to the costs associated with
teleglaucoma and in-person care to be included in the analysis. The costs to
patients for each intervention is summarized in Appendix 5. The following
assumptions were applied to estimate costs:


Travelling costs were assumed to be costs associated with personal
automobiles and did not account for potential public transit costs. Distance
travelled was converted into costs using current 2014 gas prices in Alberta
($1.26/L).27



The Grossman Health Model regarding the consumption and investment
demand for health was applied.9,10 It is assumed there is a trade-off
between time spent producing health and time spent producing other
goods. Any investments in health are reduced by time lost to illness. Thus,
there is a monetary value to time. This monetary value will be assumed as
wage rate. Time spent waiting for doctor and travelling to and from clinics
were converted to loss of productivity using Alberta average hourly wage
$29.54.23

Total Costs
All costs were summed into initial and incremental costs and cost per patient
screened was determined (Appendix 6). The initial costs were the fixed costs
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such as the initial set up fees. The incremental costs included the patient costs,
service costs, labour costs and costs associated with each health state. All costs
were converted to present value Canadian dollars and future costs were
discounted at a 3% rate. The willingness to pay applied was $40,000/QALY as
reported by literature for ophthalmic interventions.25 Uncertainties in estimated
costs were addressed using probabilistic sensitivity analysis and applying
gamma distributions (Appendix 7).
4.2.7 Effectiveness
The effectiveness of teleglaucoma is defined by its ability to detect
glaucoma. This is measured as specificity and sensitivity of the equipment
devices and the probability of being correctly screened as glaucoma positive, and
correctly screened as glaucoma negative. The sensitivity of teleglaucoma is
particularly important because it incorporates the false negatives. The false
negatives are the patients who have the disease and are incorrectly detected as
a negative test. This patient group will be told they do not have the disease and
continue living as normal. However, with glaucoma, this is particularly crucial to
avoid. Glaucoma is a silent thief of vision and if left untreated patient can lose
substantial visual acuity as well as suffer from visual defects. Thus, the sensitivity
of teleglaucoma is important to prevent glaucoma cases from leaving the clinic
without appropriate medical care.
Several studies have tested the accuracy of teleglaucoma devices with
gold standard diagnostic tools, but have reported results in kappa statistic
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agreements.28,29 However, not all studies used the same equipment and devices.
In addition, most studies were performed outside of Canada, specifically in
Kenya or India. From the literature and chapter 3, the specificity and sensitivity of
teleglaucoma were reported as 86.5% and 78.6% respectively.17
The second aspect of effectiveness is the ability of screening devices to
detect glaucoma at its early stages. The probabilities of each stage of glaucoma
at time of screening were derived from a study examining the use of
teleophthalmology.30 Corresponding with the hypothesis, a greater proportion of
individuals (46%) at mild glaucoma stage were detected with teleglaucoma. 30
The effectiveness of no screening (in-person care) was given by reported
probability of glaucoma being detected in routine in-person care.1 Fifty per cent
of glaucoma patients are undetected and are unaware of their disease state. 1
The other 50%, when presented at in-person care, these glaucoma patients are
usually at the advanced stages of the disease with progressive vision loss. The
probabilities of each glaucoma health state detected at time of in-person care
was derived from CNIB’s Cost of Vision Loss Report.1 Table 4.5 displays the
probabilities of glaucoma detection with each intervention. It also displays those
who were detected and at which health state they were in at time of screening.1
The effectiveness of teleglaucoma was also measured in its reduction of
travel time and improved access to care for people living in rural Alberta and
other remote, underserviced areas. Specifically, teleglaucoma has been
associated with savings of 4906km in travel distance and 61.23 hours of
travelling time.17,26,31 The length of time spent at the doctor visit (includes wait
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time and assessment time) with teleglaucoma was 78 minutes (~1.3 hours)
whereas with in-person care it took 115 minutes (~1.91hours).17,26
4.2.8 Utilities
The effectiveness of teleglaucoma as stated above is mainly seen by its
early detection, to initiate early treatment, to prevent progression of disease into
advanced stages. Thus, its beneficial for preserving vision. Living in each
glaucoma stage, specifically with vision loss, negatively affects one’s HRQoL.
With each glaucoma health state there is a progression of the disease. Thus with
disease progression, there is a decline in HRQoL and decreased utility value.
The utility value for each health state is 0.87, 0.79, 0.64, and 0.5, for mild,
moderate, severe, and blindness, respectively.32,33 These values are converted to
QALYs, as the ultimate unit of effectiveness for the cost-effectiveness analysis.
QALY incorporates both quality and quantity of life, specifically life expectancy,
and quality of remaining life years. QALYs are the amount of years in a person’s
life that is adjusted to represent remaining life years in perfect quality. 9 It uses
weights on time spent in different health states. Thus one year living in blind state
(utility value =0.5) is equivalent to half a year living in perfect health (utility = 1.0)
which means blind state is equivalent to 0.5 QALYs. Likewise the effect gained
from living in mild, moderate, and severe glaucoma is thus 0.87 QALYs, 0.79
QALYs, and 0.64 QALYs, respectively.
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4.2.9 Analysis Plan
This study analyzed the incremental costs, the incremental effect, and the
ICER for teleglaucoma versus in-person examination. Deterministic and
probabilistic sensitivity analyses were performed to assess the factors affecting
cost-effectiveness. Markov Cohort Analysis by 30 stages was conducted to
demonstrate the accumulated rewards, costs, and probabilities after 30 years.
Monte Carlo Simulations with the application of second-order uncertainties and
gamma and beta distributions were performed with 1000 samples. In addition,
the analysis generated the distribution of the ICERs by probability, the costeffectiveness scatterplots, and the impact of willingness-to-pay on the probability
of ICERs within an acceptability curve.
Sensitivity Analysis
Certain parameters within the model have uncertainties as discussed
above. Sensitivity analysis was conducted to determine if the uncertainties affect
the stability of the results. Deterministic sensitivity analysis was used to
determine any effects of uncertainty of costs of blindness, transitional
probabilities (at-risk to mild glaucoma and severe to blind states), and probability
of glaucoma within the population. The estimated probability of glaucoma
contains uncertainty as most cases of glaucoma go undetected and also there is
potential uncertainty in the generalizability of prevalence rates to rural Alberta.
These parameters were varied by 20% within the analysis (Table 4.2, Table 4.4).
Tornado diagrams were used to give parameters that have the most effect on
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cost-effectiveness. Probabilistic Sensitivity Analysis was also conducted to
assess uncertainty using gamma and beta distributions for uncertain costs and
probabilities respectively (Appendix 7).

4.3 Results
4.3.1 Incremental Cost-Effectiveness Ratio
The ICER for teleglaucoma screening versus in-person examination (noscreening) was established in TreeAge 2009 displaying the ratio of incremental
costs (Canadian dollars) and incremental effectiveness (QALYs) at a discounted
rate of 3% (Table 4.6).11
Teleglaucoma demonstrated to be more cost-effective than in-person care
for detecting glaucoma; the ICER was $47.60/QALY.11 This means that spending
an additional $47.60 for each patient screened with teleglaucoma will give an
additional QALY in comparison to in-person screening. The results also indicated
that teleglaucoma costs less than in-person screening when adjusted for per
patient costs and also it was more effective. Thus, the no screening option (inperson examination) is dominated by teleglaucoma screening (Figure 4.2). In
most cases, cost-effectiveness analysis are not performed under these
conditions (more effective, less costly). However, this study included long-term
effectiveness, which was not investigated previously in literature and thus this
analysis has established new information.
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4.3.2 Markov Cohort Analysis
Based on Markov Model principles, transitional probabilities are
independent of previous health states and they determine the proportion of
individuals who transition to other heath states per cycle.9,10 Markov Cohort
Analysis was conducted with 30 cycles representing 30 years.
After 30 years, teleglaucoma showed rewards for people with glaucoma
who were initially screened positive. The total reward for teleglaucoma was 15.7
QALYs, which was 1.1 less than rewards from in-person care (Table 4.7).11
However, the cumulative costs per patient for in-person care was almost 3.5
times that of teleglaucoma after 30 years, which indicated the cost-saving
associated with teleglaucoma screening. For both interventions, after 30 years
the majority of patients were blind, however it was 24% less in teleglaucoma
screening.11 Teleglaucoma also had a greater probability of preventing glaucoma
patients from progressing as 15% remained in the mild stage of glaucoma
compared to 2% with no screening.
The Markov Probability Analysis displayed how the probability of each health
state changes over the study time horizon in patients who were detected positive
for glaucoma with either intervention (Figure 4.2).11 The results demonstrated
that the probability of being at-risk for glaucoma and moderate glaucoma over 30
years (30 stages) remains relatively the same in teleglaucoma versus in-person
care. The probability of being in mild glaucoma is higher with teleglaucoma
screening, but in both interventions this probability declines with time. Similar to
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previous results, the probability of being blind was greater with in-person care
than with teleglaucoma (the concave down increasing trend of the blind state
curve in Figure 4.2b displays a closely exponential trend).11 This indicated that
teleglaucoma is more effective at preventing the probability of blindness in
glaucoma patients.
4.3.3 Deterministic Sensitivity Analysis
Deterministic sensitivity analysis was used to determine the effects of
uncertainty on the ICER results. One-way sensitivity analyses were performed on
the following variables: the costs of blindness, the transitional probabilities for atrisk to mild glaucoma and severe glaucoma to blind states (with and without
treatment). The results demonstrated that changing (+/- 20%) the costs of
blindness caused changes in the ICERs for both strategies. Teleglaucoma had
higher ICERs than inpatient screening (Figure 4.3).11 The cost-effectiveness of
teleglaucoma is affected by the costs of blindness: as costs of blindness
increases the ICER for teleglaucoma becomes smaller.
As shown in Figure 4.3d, the ICERs of inpatient screening remained
unchanged while the ICER of teleglaucoma increased very slightly as the
transitional probability of blindness increased.11 With better treatment of
glaucoma, which prevents patients from becoming blind, teleglaucoma becomes
more cost-effective (Figure 4.3d).11
The tornado diagram gives the parameters with the most effect on costeffectiveness at a willingness to pay of $40,000/QALY (Figure 4.4).11 It displays
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that the uncertainty within the prevalence of glaucoma has the most effect on the
ICER and it has the largest range of net monetary benefits. The results suggest
the transitional probabilities for at-risk to mild and severe to blind have more of
an effect on the cost-effectiveness of teleglaucoma as well as the cost of
blindness. Whereas, the transitional probability for severe to blind without
treatment and at-risk to mild with treatment had less effect on the costeffectiveness of teleglaucoma.
4.3.4 Probabilistic Sensitivity Analysis
Gamma and beta distributions were applied to the Markov Model. Monte
Carlo Simulation second order was conducted and the statistics report gave a
mean cost of teleglaucoma as $866.90 ± 113.10 per patient screened compared
to in-person screening which has a mean of $4419.8 ± 1044.70. The results
showed teleglaucoma costs less per patient than in-person screening.
The results of the Cost-effectiveness scatterplot demonstrate that there is
a greater uncertainty with the costs and effectiveness of “in-person screening”
(in-person care) as the dots of the graph are widely spread apart giving costs
from approximately $3K-8K (Figure 4.4).11 However, there is less uncertainty with
the costs of teleglaucoma, since the dots are tightly plotted around $1K (Figure
4.4).11 This means that the ICER of in-person care is more sensitive to the costs
than the ICER of teleglaucoma whereas teleglaucoma ICER is more sensitive to
the effectiveness in comparison to in-person care. The results of the sensitivity
analysis on willingness to pay demonstrate that neither teleglaucoma nor in-
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person care is sensitive to changes in WTP as the line remains relatively
constant as WTP changes (Figure 4.5).11 Only after WTP increases above
$60,000, the probability of cost-effectiveness for teleglaucoma becomes slightly
less cost-effective versus in-person screening which becomes slightly more costeffective. However, in comparison to in-person screening teleglaucoma is 100%
more cost-effective.

4.4 Discussion
Teleglaucoma is beneficial to remote areas as the physician is not
required to see patients in person. This reduces wait times and shortens the
length of ophthalmic consultations. Teleglaucoma avoids long distance travel and
time wasted on commuting. Our results demonstrated the direct benefits to
patients was a cost savings of ~$2474.60 with teleglaucoma. The early detection
approach of teleglaucoma successfully reduced the probability of patients at the
blind stage of glaucoma by 24% and maintained 13% more patients at the mild
stage glaucoma in comparison to in-person care. The long-term benefits of early
detection was confirmed by this CEA with greater cumulative rewards and cost
savings 30 years post-detection. When assessed on its own, teleglaucoma was
more cost-effective than in-person care with an ICER of -$27,460 per QALY (cost
per patient serviced) meaning teleglaucoma saved $27,460 per QALY gained
relative to in-person examination. The large direct patient savings and reduced
costs of blindness due to preservation of vision, mainly accounted for its
effectiveness. The ICER of teleglaucoma was only sensitive to the probability of
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glaucoma. This is logical since positive predictive values of screening tools
fluctuate with changing prevalence rates and changing prevalence rates will alter
the probability of glaucoma. As the probability of having glaucoma increases,
teleglaucoma had greater cost-effectiveness.
At a willingness to pay of $40,000/QALY, teleglaucoma is cost-effective
when compared with in-person care.25 In addition, the World Health Organization
provides the threshold for cost-effective interventions: an intervention is
considered cost-effective if the ICER associated with implementation of the
intervention is less than the country’s GDP.34 Teleglaucoma has an ICER below
Alberta’s GDP and thus, teleglaucoma is cost-effective for Alberta’s population.
Several studies have analyzed the effectiveness of teleglaucoma in terms
of its ability to detect glaucoma and proposed reduction in direct patient costs,
however, none have produced a complete cost-effectiveness analysis.17 Analysis
of teleophthalmology for other ocular conditions such as diabetic retinopathy,
have also shown to be cost-effective with ICERs of $1320/QALY in a similar rural
setting based on the data of 326 patients from rural India. 35
The strength of this study is it indicated that although the base cost of
teleglaucoma is large, the variable cost is lower per year. In return, the benefits
outweigh costs over time. In addition, this study includes indirect costs such as
loss of productivity and opportunity costs of time. By including the patient, the
healthcare provider, as well as the Ministry of Alberta perspectives, a societal
perspective is developed providing a broad scope on the cost-effectiveness of
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teleglaucoma. This CEA is focused on screening for a targeted population who is
above the age of 50 years and at-risk of glaucoma in rural Alberta, which is
another strength of this study. Mass screening of total populations are not costeffective as it wastes resources with small benefits. In addition, this CEA applied
Markov Modelling to illustrate the progression of glaucoma through transitional
health states over time. This is beneficial to predict the long-term benefits of
teleglaucoma. Costs were also discounted at a 3.0% rate to account for future
value. Most studies have reported only the patient’s present benefits at time of
the teleglaucoma screening, but have not analyzed the aftermath. Thus, with a
time horizon of 30 years this CEA contributes to literature by illustrating
teleglaucoma enables early detection, and, as a result, it delays the progression
of glaucoma and preserves vision.
One of the limitations for the CEA is that because no studies have
analyzed the long-term benefits of teleglaucoma, estimates of transitional
probabilities were derived from non-teleglaucoma studies. In addition, there is a
lack of RCT data on teleglaucoma as most studies are observational. Of the
observational studies that did look at the effectiveness of teleglaucoma, most
focused on diagnostic accuracy, patient satisfaction, and reduced patient costs,
but did not examine clinically relevant outcomes such as reduction in patients
with vision loss.
In conclusion, a cost-effectiveness analysis of teleglaucoma was
successfully performed to demonstrate that implementing teleglaucoma in rural
Alberta and targeting at-risk population is cost-effective in comparison to no
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screening. Early detection of glaucoma allows necessary medical care to prevent
progression of the disease. Glaucoma is a chronic progressive disease with no
cure and thus this CEA provides valuable prognosis information. Teleglaucoma
can have long-term benefits on preservation of vision in those with glaucoma.
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4.6 Tables
Table 4.1: Standardized Teleglaucoma Equipment
Human Resources
Ophthalmic
technicians,
Physicians,
glaucoma
specialists/
ophthalmologists,
Graders,
Optometrist

Information
Technology
Secure Diagnostic
Imaging (SDI)
system,
Videoconferencing
equipment,
Computer systems
and software

Screening
Equipment

Examinations

Retinal camera,
Tonometer,
Devices to
measure central
corneal
thickness,
Frequency
Doubling
Technology
(FDT) or
Humphrey Visual
Field test,
Optical
Coherence
Tomography, Slit
lamp,
Gonioscope,

Medical & family
history, Visual
acuity, IOP,
CCT, OCT, Slit
lamp,
Gonioscopy,
Visual field, Pupil
equal and
reactive to light
(PERL) or
relative afferent
pupillary defect
(RAPD), Fundus

Retinal camera,
Devices to
measure central
corneal
thickness

photographs,
Ancillary tests

Footnote: Thomas S-M, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta
MS. (2014) The Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma
Screening: A Systematic Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:
10.1371/journal.pone.0113779. pmid:25479593
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Table 4.2: Transitional Probabilities for Glaucoma Health States
Transitional
Sensitivity
Health States
Probability
Analysis
Range
At-Risk to Mild
0.20
0.16-0.24
Glaucoma
Mild to Moderate
0.04
Glaucoma
Moderate to Severe
0.10
Glaucoma
Severe Glaucoma to
0.15
0.12-0.18
Blind
At-Risk to Mild
0.48
0.38-0.58
Glaucoma
Mild to Moderate
0.26
Glaucoma
Moderate to Severe
0.5
Glaucoma
Severe Glaucoma to
0.5
0.4-0.6
Blind

Reference

Treated

Stein, 201235

Untreated

Fechtner,
200436
Chen, 201437

Fechtner,
200436

Table 4.3: Direct Costs of Teleglaucoma and in-person Care
Teleglaucoma

in-person Care

Total Fixed Costs ($)
Set-up (Service and

416,600

243,146

1,256,142

329,833

Training)
Technology Equipment

Variable Costs ( $ costs per patient screened)
Labour

348

248.98

Service

370.89

309.90

Derivation of costs are found in Appendix 8.
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Table 4.4: Costs associated with each health state
Health State

Costs ($)

At-Risk

623

Mild Glaucoma

1480

Moderate
Glaucoma

3682

Severe
Glaucoma

4975

Blindness

33666

Sensitivity Analysis

26,932.80 - 40399.20

Derivations of costs can be found in Appendix 9.

Table 4.5: Probabilities of glaucoma detection and associated health states
Probability of
Being Detection

Probability of each health state
detected

Sensitivity Specificity

Teleglaucoma

Atrisk

Mild

Moderate Severe

Blind

0.59

0.96

0.03

0.46

0.5099

0.0001

0

in-person care 0.50

0.50

0

0.08

0.52

0.30

0.1

Table 4.6: Summary of ICER Data

Strategy
Teleglaucoma
Screening

Cost

871.54

Incremental
Cost

Effect

18.32

Incremental
Effect

Cost/Effect

ICER

47.57

in-person
Screening
4441.42
3569.88
18.19
-0.12
244.05 (Dominated)
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).
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Table 4.7: Accumulate Rewards, Costs, and Probabilities after 30 years
Cumulative Cumulative
Costs ($)

Probability at each health state

Rewards
(QALY)

At-

Mild

Moderate

Severe

Blind

0.15

0.10

0.09

0.65

0.02

0.04

0.05

0.89

Risk
Teleglaucoma

3.71E1155.45

15.7

0

In-person/ no
screening

05

4035.19

16.8

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).

4.7 Figures
Figure 4.1: Markov Model Transitional Health States
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Figure 4.2: Cost-Effectiveness Analysis

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).

Figure 4.3: Markov Probability Analysis of Health States

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).
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Figure 4.4: DSA One-Way Sensitivity Analysis
Figure 4.4a. Variable: Cost of blindness

Incremental Cost/Eff

1000
500
0
Teleglaucoma
Screening

-500
-1000

Inpatient Screening

-1500
-2000
0

200000

400000

600000

Cost of Blindness

Figure 4.4b. Variable: Probability of Transitioning to Mild Stage Glaucoma

Incremental Cost/Eff

600
500
400
300

Teleglaucoma
Screening

200

Inpatient Screening

100
0
0

0.2

0.4

0.6

0.8

Transitional Probability to Mild Glaucoma
(without treatment)

1
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Figure 4.4c. Variable: Transitional Probability to Blind stage Glaucoma

Incremental Cost/Eff

600
500
400
Teleglaucoma
Screening

300
200

Inpatient Screening

100
0
0

0.2

0.4

0.6

0.8

1

Transitional Probability to Blind stage Glaucoma
(without treatment)

Figure 4.4d. Variable: Transitional Probability to Blind Glaucoma

Incremental Cost/Eff

600
500
400
Teleglaucoma
Screening

300
200

Inpatient Screening

100
0
0

0.2

0.4

0.6

0.8

1

Transitional Probability to Blind Glaucoma
(with treatment)
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).
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Figure 4.5: Tornado Diagram for At-Risk Population

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).
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Figure 4.6: Cost-Effectiveness Scatterplot

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).

Figure 4.7: Acceptability Curve

Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7).
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Chapter 5 Integrated Discussion
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5.1 Overview
This chapter outlines the thesis results, interpretations, and generates the
thesis conclusions. In summary, the objectives of the thesis were (1) to
determine the effectiveness of teleglaucoma in its capability to accurately
discriminate between positive and negative cases and (2) to determine the costeffectiveness of teleglaucoma as a screening device.

5.2 Integrated Discussion of Thesis Results
This thesis synthesized published and unpublished research literature on
the diagnostic accuracy of teleglaucoma. The meta-analysis found that the
specificity and sensitivity were 0.79 [0.67, 0.88] and 0.83 [0.77, 0.88]
respectively. The Canadian Ophthalmology Society (COS) criteria for the
minimum effectiveness of tele-ophthalmology is a sensitivity of at least 80% and
a specificity of at least 90%.1 Thus, according to COS standards teleglaucoma
does not meet the minimum requirements for an effective screening tool.
However, it is important to note that in comparison to the standard of care,
teleglaucoma had a greater specificity than in-person examination, but was not
as sensitive as in-person examination. Thus, although teleglaucoma does not
meet Canadian standards, it is more effective than the current practice.
Teleglaucoma demonstrated low false negative and high true positive
rates. This is an indication of a good screening tool for glaucoma.2 Glaucoma is a
progressive disease that becomes worst when untreated. False positive cases
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are left untreated and may progress to advanced stages of the disease. 2 For
glaucoma specifically, it is important to detect the disease earlier to allow for
early intervention and to prevent vision loss. Thus, this thesis has successfully
demonstrated that teleglaucoma is beneficial to preventing visual impairment
overall. However, the false positive rates are higher than in-person examination
which seemingly introduces potential issues related to teleglaucoma.
A false positive means a patient thinks they have the disease, when they
actually do not. With some diseases such as cancer, the patient may experience
depression and psychological stress as a response to their screening result.
However, with glaucoma, because the disease progression is slowed with
treatment, the likelihood of serious consequences is low. This in return removes
the risk of serious patient psychological consequences. In addition, the
confirmatory test for glaucoma occurs within two months which is a relatively
short time for a patient to wait to confirm their disease status. Prior to screening
the patient receives consultation on the consequences of test results to ensure
the patient is informed and to minimize the physiological risks of false positives.
The confirmatory diagnosis conducted by the ophthalmologist involves very
minimal risks.2 Thus although, generally speaking a false positive is not good
practice, with glaucoma there is very minimal risk to patient.
In addition, the results were based on optimizing the use of several
glaucoma diagnostic instruments for screening. Several studies have reported
the differences in diagnostic accuracy based on the various combinations of
diagnostic instruments. With greater amounts of diagnostic instruments used to
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examine glaucoma patients, the higher the accuracy of the screening process.
The instruments used in this analysis, which defined teleglaucoma, were based
on the minimum requirements set by Canadian Medical standards.3
In addition, teleglaucoma was able to detect greater proportions of
glaucoma cases in comparison to in-person examination. This was an important
finding as early detection plays an important role in preventing glaucoma
progression. If caught early and treatment is initiated, glaucoma can be managed
and patients can have preserved vision. The long term benefits of teleglaucoma
found that in comparison to in-person examination, teleglaucoma prevents more
cases of blindness.
Blindness lowers one’s health-related quality of life (HRQoL) and limits
one’s independence. As glaucoma progresses through its health states, the
quality of adjusted life years (QALYs) declines. The “blindness” health state is
represented by 0.5 QALYs whereas the “at-risk” health state is represented by
0.87 QALYs.4,5 As glaucoma progresses to advance stages it also becomes
more costly to manage and treat. Moreover, it is expected that if teleglaucoma
detects more cases of glaucoma and at earlier stages, then blindness can be
prevented. This study successfully found that teleglaucoma prevents 24% of
cases, in the long term, in comparison to in-person examination.
The second section of this thesis examined the cost implications of
teleglaucoma. The direct and indirect costs of teleglaucoma system, which were
synthesized systematically through the meta-analysis, were applied to the
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Markov Model. The costs and the measure of quality of life of each health states
were included in the analysis. Through the meta-analysis, the effectiveness of
teleglaucoma was measured in specificity and sensitivity and was applied to the
Markov Model. When taking all costs into consideration, teleglaucoma displayed
reduction of costs. Furthermore, in terms of the effectiveness of teleglaucoma,
this thesis found that teleglaucoma added 0.12 QALYs per each patient
screened. This is a significant improvement in HRQoL when taking into
consideration the time frame. The analysis used an annual time frame and all
costs and benefits are thus based on yearly outcomes. Therefore, although a
0.12 QALY increase may not be a large impact over many years, a 0.12 QALY
increase per year is a substantial difference in HRQoL. In conclusion, it was
found that teleglaucoma is more cost-effective than in-person examination.

5.3 Thesis Limitations and Knowledge Gaps in Current
Literature
There were limitations within this thesis study. The systematic review
included studies written in English only. By excluding potential articles based on
language, this may bias the results. It would essentially produce results valid to
English speaking countries mainly. Statistically, this reduces sample size,
whereby limiting the power of the results.
The quality of the study evidence varied and despite variation, all studies
were included in the systematic review and meta-analysis. The quality of
evidence was based on the risk of bias, imprecision, inconsistency, and
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indirectness.6-11 Of the 45 studies included in the systematic review, only 17 were
of high quality based on the GRADE guidelines. High quality studies are those
that have a high confidence that the true effect lies close to that of the estimate
effect based on the fact there is no or minimal bias.6-11 Thus, the majority of
studies provided quality of evidence which were of low or moderate levels. The
quality of evidence limits the validity of the results and thus, in return limits the
accuracy of the synthesized results.
The meta-analysis section took into account the sample size and standard
errors of each study which minimizes the risk of bias. However, all studies were
observational studies and this reduces the quality of evidence. Observational
studies lack a controlled environment and patients are not necessarily
randomized.12 This reduces the confidence that the treatment intervention is
responsible for the differences in results. In contrast, randomized control trials
(RCT) provide high level quality of evidence and due to gaps in the research
literature; no RCTs have been conducted on teleglaucoma.12,13 Observational
studies provide a moderately good level of evidence, however they cannot
control for all factors that may influence the study results. This indicates the need
for more RCTs on this topic. Nonetheless, as the effectiveness of teleglaucoma
includes the healthcare service quality, it is beneficial to highlight the
teleglaucoma service in real-time through observational studies.
In addition, there was variability in the clinical characteristics reported by
studies. Some studies focused on the specificity and sensitivity of teleglaucoma
only and did not include a comparator. Some studies used various technologies
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as part of their teleglaucoma system. There is expected variation in the
technology quality and to minimize bias, only current studies were included.
Another limitation of the systematic review is the sample size. There were
only ten studies used in the meta-analysis section. Of those ten studies, only five
compared teleglaucoma to a comparator. When conducting a systematic review,
the larger the sample size, the more evidence it will provide. Sample size is
important for statistical reasons. For instance, the smaller the sample size, the
more standard error and the lower the power of the results.14 It also limits the
confidence in the results. Thus, a sample size of ten is fairly small. Unfortunately,
systematic reviews are dependent on the literature. Although, a comprehensive
systematic search of published and unpublished literature was conducted, the
results may not be representative of the actual service quality due to research
gaps in literature. This suggests more literature is required on the effectiveness
of teleglaucoma in general, and also on teleglaucoma in comparison to in-person
examination.
Common bias affecting systematic reviews is publication bias which is the
selective publication of certain types of studies.12 To minimize publication bias,
published and unpublished research databases were searched and articles from
both sources were included. Thus, from the assessment, publication bias was
minimal in this systematic review.
There were a few assumptions made during the CEA that may limit the
external validity of this thesis. The main limitation is the study population; this
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analysis applies only to rural populations, more specifically rural Alberta.
Therefore, all costs, the healthcare system model, glaucoma prevalence, and
patient demographics derived were based on Alberta. Importantly, the distance
required for patients to travel is based on distances in Alberta. The costeffectiveness of teleglaucoma is highly dependent on patient savings from the
reduction in travel distance, time, and costs. Thus, the external validity of the
study is restricted to populations similar to Alberta. In order to determine if
teleglaucoma is cost-effective for a specific area, a CEA based on that specific
population is required, as distances, currencies, and patient demographics
change according to area. Importantly, the prevalence of glaucoma in the study
population effects the cost-effectiveness. If the prevalence of glaucoma is higher,
teleglaucoma becomes more cost-effective. This thesis assumed a prevalence of
glaucoma found in Alberta, which may or may not be similar to other provinces or
populations.
There was limited access to official costing sources such as specific
Alberta hospital budgets. Thus, the actual costs for servicing a teleglaucoma
clinic in its totality could not be determined accurately. Labour costs were
estimated based on average Alberta physician and healthcare provider incomes.
The costs used in the analysis were derived from published data and expert
opinion. Thus, the total fixed and variable costs are estimates based on quotes
from research literature required to service a teleglaucoma system. Some of the
research literature were Canadian, but the majority of costing sources were
European or American studies which may not represent Alberta best. Because of
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the lack of official data sources, this thesis made assumptions that the costs
would be similar in Alberta. Where possible, hospital data from London, Ontario
from 2014 was used to at least have current and Canadian data. Examples of
these estimates were the costs of ophthalmic instruments. Likewise, the costs of
the comparator intervention were also derived from estimates, quotes, and
published data which may not accurately represent Alberta. These limitations and
resulting assumptions can create some inaccuracies in the results of the CEA
and the internal validity of the costing analysis. It can bias the results in either
way: cause teleglaucoma to become more cost-effective or in-person
examination to become more cost-effective.
From the thesis results, a large proportion of teleglaucoma cost-savings
was attributed to the reduction in direct patient costs (travel and wait times).
Although travel times and wait time were sourced from published research
literature based on Alberta’s population, there were some limitations in the
translation of data into costs. Firstly, only a few studies reported the travel
distances and wait times, thus the power was limited by sample size. Secondly,
the conversion of wait times and travel times into productivity loss was based on
the assumption that patients were employed and earned an average Alberta
salary. Glaucoma is a disease of the elderly and a proportion of patients may not
be employed, but rather retired. The employment status and exact salaries of
glaucoma patients at the Alberta teleglaucoma clinics are inaccessible and thus
estimates had to be used.
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Nevertheless, this raises an important issue of value of patient’s time.
Although, the patient is unemployed and may not have employment income,
firstly, they may have income from other sources (such as pensions, RRSPs, or
investment incomes). These sources of income are private data and may not be
reported in literature.15 As a result, income from other sources are challenging to
quantify and estimate. Secondly, based on the Grossman model, it can be
argued that those who are unemployed should not have the same monetary
value as employed people and rather have a lower monetary value.16 This is
ethically incorrect because a person’s time is valuable with or without
employment. Additionally, the value of the time spent by the unemployed cannot
be assumed to be less than the value of the time of the employed.16 The
unemployed, retired, and disable proportions of the study population although
may not work, but their time still has equal value as any other employed person.
Thus, when placing a monetary value on the study population it was important to
consider this and to not treat any group differently. Given these challenges and
reasons, the assumption to place the average wage salary as the monetary value
of the patient’s time was the best solution as it was most practical and just option.
A simplified model of productivity loss was used which included solely
employee wages. The costing model did not include other measures of
productivity, nor societal costs and indirect patient costs such as the
psychological costs or opportunity costs. Furthermore, patient compensation
resources such as health insurance model were not incorporated into the costing
models. Therefore, these estimates can bias the thesis results and create
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limitations to the internal validity of the cost-effectiveness analysis. Fortunately,
to minimize these inaccuracies, sensitivity analysis were performed. However, to
improve this thesis, a full costing evaluation of current teleglaucoma service
using precise sources is recommended.
Similarly, the probabilities were derived from research literature and expert
opinion and assumptions were made in order to derive the estimated
probabilities. For example, the transitional probabilities assumed patients were
either treated or untreated irrespectively at the same rate. That is, the probability
a patient will transition to another glaucoma health state when “treated” assumed
75% patient’s compliance with treatment at all health states. Whereas “untreated”
implied patients receive no treatment at all health states. Since the transitional
probabilities may differ based on treatment paradigms used, uncertainties can
develop. Likewise, the Markov Model probabilities are influenced by many
factors. Estimates and derivations of the probabilities of each of these factors
increases the likelihood of uncertainties and thus can bias the thesis results.
Lastly, the outcome measure used in the analysis was costs per QALY
gained ($/QALY). Although this is a universal measure that allows standardized
comparison across healthcare disciplines, it is acknowledged that there may be
other useful outcome measures. “Costs per detected case” allows a more
immediate measure of the direct benefits of teleglaucoma. This outcome
measure can be more practical for clinicians and healthcare administrators; it is
easier to understand and apply to daily clinical practice. It allows direct
comparison among programs which have the same goals.17 For future research,
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it is recommended to add the “cost per detected case” measure to obtain the
immediate benefits and costs to the healthcare system. Immediate outcome
measures are useful for health policy decision-makers as it provides a simple
decision criterion for resource allocation without the consideration of many
uncertainties related to calculating long-term benefits.17 Although, “costs per
detected case” is a tangible outcome measure, unlike “$/QALY”, it excludes
quality of life measures and may not capture all important benefits.
Consequently, in addition to “$/QALY”, “costs per detected case” is a useful
outcome measure to enhance the cost-effectiveness analysis of teleglaucoma.

5.4 Conclusions and Future Directions
In conclusion, this thesis has found teleglaucoma is more specific and less
sensitive than in-person examination and it is more cost-effective screening
device for glaucoma in rural populations. To optimize the results, there are
several recommendations for future study directions. Future studies can examine
the use of teleglaucoma in semi-urban and urban areas; its potential benefits and
its cost-effectiveness. The main advantage of teleglaucoma in rural populations
is the convenience and the reduction in patient travel costs. However,
teleglaucoma can play a role in urban populations. Urban hospitals can be
overflown with patients placing a burden on the healthcare system and
prolonging patient wait times. Teleglaucoma can act to reduce patient load at the
hospital and therefore, improve the efficiency of ophthalmology clinics. It is
speculated that there will be cost-savings with the implementation of
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teleglaucoma in urban settings, and teleglaucoma can be cost-effective in these
settings as well. Direct benefits are expected from the decline of patient load at
ophthalmic clinics, which translates into reduced patient wait times and minimize
unnecessary ophthalmic visits. However, the cost-effectiveness in urban, cities
such as Calgary or Edmonton, may not be as comparable to that of rural Alberta,
because the main cost-savings found in rural areas was the reduction of patient
costs due to reduced travel distances and times. In urban cities, there are more
ophthalmic centers and increased access to ophthalmic care in comparison to
rural areas. Thus urban patients may not have to travel as far to receive
ophthalmic care. Nonetheless, urban cities are more populated than rural cities.
From an economic perspective, this is beneficial as it would allow the service to
reach a greater population. Consequently, future studies are needed to examine
the use of teleglaucoma in urban populations and its cost-effectiveness. And
when comparing implementation in either setting (urban or rural) special caution
needs to be taken with regards to ethical resource allocation based on equity
versus efficiency and demand versus need.
This thesis has identified gaps in literature which can help guide future
studies. There is demand for randomized controlled trials on teleglaucoma to
provide high quality of evidence. More comparative studies are required which
analyze teleglaucoma against a comparator, specifically in-person examination,
the standard of care. Future studies can examine the long term benefits of
teleglaucoma. Most studies included in the thesis analysis examined the benefits
of teleglaucoma directly after screening and long term benefits were not included.
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Glaucoma is a chronic, progressive disease affecting the elderly and has long
term consequences if not managed appropriately. Thus, more studies analyzing
the long term benefits of screening are beneficial to patient outcomes.
In addition, future reviews and CEAs should examine the use of
teleglaucoma systems within optometrist or pharmacist clinics. These clinics are
pre-established within rural areas and are usually more abundant than
ophthalmologist clinics. Placement of teleglaucoma systems within optometrist or
pharmacist clinics can reduce overhead costs and essentially prove to be even
more cost-effective.
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Appendix 2: Systematic Review Search Strategies
DATABASE
OVID Medline

SEARCH TERMS
1
2

3
4
5

6
7

8

9
10
RESULTS

Exp Glaucoma/ OR Intraocular Pressure/ OR Ocular
hypertension/
Glaucoma* OR Intraocular pressure OR Intra-ocular pressure
OR Intraocular hypertension OR Intra-ocular hypertension OR
Intra-ocular tension OR Intraocular tension OR Ocular
hypertension OR Ocular tension OR Eye tension OR Eye
pressure
1 OR 2
Remote consultation/ OR Telemedicine/ OR Telepathology/
OR Mobile Health Units/ OR Community Pharmacy Services/
Automated detection OR Teleglaucoma OR Telescreen* OR
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR
Telemedicine OR Tele-medicine OR digital indirect
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR
Teleconsult* OR Tele-consult* OR Telediagnos* OR Telediagnos* OR Telehealth OR Tele-health OR Mobile health OR
eHealth OR Automated Perimetry Exam*
4 OR 5
Diagnosis/ OR Early diagnosis/ OR Diagnostic Techniques,
Ophthalmological/ OR Tonometry, Ocular/ OR Diagnosis.fs.
OR Vision screening/ OR Mass screening/ OR Visual Field
Tests/
Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr*
OR Campimetr* OR Visual field test* OR
Oculplethysmograph* OR Vision test* OR Early diagnosis
7 OR 8
3 AND 6 AND 9
86
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present

OVID EBMASE
1
2

3
4

5

Exp glaucoma/ OR Intraocular pressure abnormality/ OR
Intraocular pressure/
Glaucoma* OR Intraocular pressure OR Intra-ocular pressure
OR Intraocular hypertension OR Intra-ocular hypertension OR
Intra-ocular tension OR Intraocular tension OR Ocular
hypertension OR Ocular tension OR Eye tension OR Eye
pressure
1 OR 2
Telemedicine/ OR Telehealth/ OR Telediagnosis/ OR
Telepathology/ OR Teleconsultation/ OR Telemonitoring/ OR
computer assisted perimetry/
Automated detection OR Teleglaucoma OR Telescreen* OR
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6
7

8

9
10

Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR
Telemedicine OR Tele-medicine OR digital indirect
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR
Teleconsult* OR Tele-consult* OR Telediagnos* OR Telediagnos* OR Telehealth OR Tele-health OR Mobile health OR
eHealth OR Automated Perimetry Exam*
4 OR 5
diagnosis/ OR early diagnosis/ OR diagnostic accuracy/ OR
diagnostic test accuracy study/ OR diagnostic value/ OR
perimetry/ OR oculoplethysmography/ OR vision test/
Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr*
OR Campimetr* OR Visual field test* OR
Oculplethysmograph* OR Vision test* OR Early diagnosis
7 OR 8
3 AND 6 AND 9
Embase Classic+Embase 1947 to 2014 March 11

CINAHL
1

9
10

(MH "Glaucoma+") OR (MH "Ocular Hypertension") OR (MH
"Intraocular Pressure")
Glaucoma* OR Intraocular pressure OR Intra-ocular pressure
OR Intraocular hypertension OR Intra-ocular hypertension OR
Intra-ocular tension OR Intraocular tension OR Ocular
hypertension OR Ocular tension OR Eye tension OR Eye
pressure
1 OR 2
(MH "Telehealth") OR (MH "Telemedicine") OR (MH "Remote
Consultation") OR (MH "Telepathology") OR (MH "Mobile
Health Units")
Automated detection OR Teleglaucoma OR Telescreen* OR
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR
Telemedicine OR Tele-medicine OR digital indirect
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR
Teleconsult* OR Tele-consult* OR Telediagnos* OR Telediagnos* OR Telehealth OR Tele-health OR Mobile health OR
eHealth OR Automated Perimetry Exam*
4 OR 5
(MH "Diagnosis") OR (MH "Diagnostic Services") OR (MH
"Diagnosis, Eye") OR (MH "Tonometry") OR (MH "Vision
Screening") OR (MH "Vision Tests") OR (MH "Perimetry") OR
(MH "Early Diagnosis")
Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr*
OR Campimetr* OR Visual field test* OR
Oculplethysmograph* OR Vision test* OR Early diagnosis
7 OR 8
3 AND 6 AND 9

1

Glaucoma* OR Intraocular pressure OR Intra-ocular pressure

2

3
4

5

6
7

8

Cochrane,
Web of
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Science,
BIOSIS,
Dissertations
and Thesis,
Canadian
Health
Research
Collection

2

3

4

OR Intraocular hypertension OR Intra-ocular hypertension OR
Intra-ocular tension OR Intraocular tension OR Ocular
hypertension OR Ocular tension OR Eye tension OR Eye
pressure
Automated detection OR Teleglaucoma OR Telescreen* OR
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR
Telemedicine OR Tele-medicine OR digital indirect
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR
Teleconsult* OR Tele-consult* OR Telediagnos* OR Telediagnos* OR Telehealth OR Tele-health OR Mobile health OR
eHealth OR Automated Perimetry Exam*
Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr*
OR Campimetr* OR Visual field test* OR
Oculplethysmograph* OR Vision test* OR Early diagnosis
1 AND 2 AND 3

Footnote:
1.

Thomas, Sera-Melisa; Jeyaraman, Maya; Hodge, William G.; Hutnik, Cindy; Costella, John;
Malvankar-Mehta, Monali S. (2014): The Effectiveness of Teleglaucoma versus In-Patient
Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis. Table_S1.docx.
PLOS ONE. 10.1371/journal.pone.0113779.s001. Retrieved 16:24, Jan 20, 2015 (GMT).
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Appendix 3: Hierarchical Logistic Regression Results
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Appendix 4: Markov Model Decision Tree
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Appendix 5: Estimated Direct Costs to Patients
Unit

$/unit

Cost ($)

Source
Teleglaucoma
CBC, 20141

Travel distance (km)

0

$1.264/Liter*0.0

0

89L/km

StatsCan,
2013

2

Travel time (hour)

0

$29.54/hr

0

Duration of Doctor visit

1.3

$29.54/hr

38.40

3.3

$29.54/hr

97.48

(hour)
Absence from work
(hour)
TOTAL

135.88

In-person Care
CBC, 20141

Travel distance (km)

4906

$1.264/Liter

551.90

x0.089L/km

StatsCan,
20132

Travel time (hour)

61.23

$29.54/hr

1808.73

Duration of Doctor visit

1.91

$29.54/hr

56.6

6.6

$29.54/hr

194.96

TOTAL

2612.19

(hour)
Absence from work
(hour)

Footnote:
1.
2.

Canadian Broadcasting Corporation (CBC). (2014). Alberta Gas Prices. Available:
http://www.cbc.ca/calgary/features/gasprices/ Accessed 2014 Mar 3.
Statistics Canada (StatsCan) (2014). Earnings, average weekly, by province and territory. Available
online <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm>
Accessed 2014 Mar 3.
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Appendix 6: Total Cost Data (Cost per patient serviced)
Combined Practice
Cost Type

Parameters Included

Teleglaucoma

in-person

(Teleglaucoma + inperson)

Initial

Fixed costs

Incremental Patient costs, service
costs, labour,

41.87

2.39

44.26

855.38

57809.74

58665.12

Appendix 7: Distribution for Probabilistic Sensitivity Analysis

Index
1
2
3
4
5
6
7
8
9
10
11
12
13

Variable Name
dist_cost_blind
dist_cost_inpat_incr
dist_cost_inpat_initial
dist_cost_tele_initial
dist_cost_tele_incr
dist_probAtrisktomild_no_txt
dist_prob_atrisktomild_txt
dist_prob_mildtomod_txt
dist_prob_mildtomod_no_txt
dist_prob_mod2sev_no_txt
dist_prob_modtosev_txt
dist_prob_sev3blind_no_txt
dist_prob_sev2blind_txt

Type
Gamma
Gamma
Gamma
Gamma
Gamma
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta

Param 1
34.5
95.2
1
99.2
89.2
64.2
75.2
89.63
88.21
98.22
54
29.336
30.582

Param 2
0.001
0.03
0.00003
0.085
0.8
41
45.3
78.21
165.23
54.22
7.52
170.253
180.42

Sample Rate Option
0
0
0
0
0
0
0
0
0
0
0
0
0

2
2
2
2
2
2
2
2

Help/Explanation
Param 1 = alpha; Param 2 = lambda
Param 1 = alpha; Param 2 = lambda
Param 1 = alpha; Param 2 = lambda
Param 1 = alpha; Param 2 = lambda
Param 1 = alpha; Param 2 = lambda
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
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Appendix 8: Derivation of Costs for teleglaucoma and in-person care

139

Footnote:
1.
2.
3.
4.
5.

6.

7.

Tuulonen A, Ohinmaa A, Alanko H, et al. (1999) The application of teleophthalmology in examining
patients with glaucoma: a pilot study. J Glaucoma 8: 367–73.
Bank of Canada. (2014) Daily Currency Converter. Available:
http://www.bankofcanada.ca/rates/exchange/daily-converter/.
Statistics Canada (StatsCan) (2014). Earnings, average weekly, by province and territory. Available
online <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm>
Government of Alberta (2014). Medical Procedures Lists. Available online:
<http://www.health.alberta.ca/documents/SOMB-Medical-Procedures-2014-04.pdf>
Thomas S-M, Jeyaraman MM, Hodge WG et al. (2014) The Effectiveness of Teleglaucoma versus
In-Patient Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis. PLoS
ONE 9(12): e113779. doi: 10.1371/journal.pone.0113779. pmid:25479593
Arora S, Rudnisky C, Damji K (2014) Improved Access and Cycle Time with an “In-house” patientcentered teleglaucoma program versus traditional in-person assessment. Telemed J E-Health
20(5):439-45.
Ng M, Nathoo N, Rudnisky C et al. (2009) Improving Access to Eye Care: Teleophthalmology in
Alberta, Canada. J Diabetes Sci Technol 3(2): 289-296.
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Appendix 9: Costs Associated with each health state

Glaucoma Stage

Costs
($/patient)

Author

0

623

Lee, 20061

1

1480

2

1765

3

1917

4

2464

5

2511

Health State

Derivative

Costs

Author

($/patient)

At-Risk

= Stage 0 costs

623

Mild Glaucoma

= Stage 1 costs

1480

= Stage 2 + Stage 3 Costs

3682

= Stage 4 + stage 5 costs

4975

= $2,613M (total costs of vision loss in Alberta)

33666

Moderate

Lee, 20061

Glaucoma
Severe Glaucoma
Blindness

CNIB, 20082

x 77,615 people with vision loss in Alberta)

Footnote:
1.

2.

Lee PP, Walt JG, Doyle JJ, et al. A Multicenter, Retrospective Pilot Study of Resource Use and
Costs Associated With Severity of Disease in Glaucoma. Arch Ophthalmol. 2006;124(1):12-19.
doi:10.1001/archopht.124.1.12.
CNIB and the Canadian Ophthalmology Society. (2008) Costs of vision loss in Canada: Summary
report. Available online:
http://www.cnib.ca/eng/CNIB%20Document%20Library/Research/Summaryreport_Covl.pdf
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